Modulation of the fecal metabolome to reduce diarrhea using resistant starch supplementation

WO2026232220A1PCT designated stage Publication Date: 2026-11-12MCPHARMA BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050538
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-15
Filing Date
2026-04-09
Publication Date
2026-11-12

Smart Images

  • Figure IMGF000045_0001_TABLE
    Figure IMGF000045_0001_TABLE
  • Figure IMGF000045_0002_TABLE
    Figure IMGF000045_0002_TABLE
  • Figure IMGF000045_0003_TABLE
    Figure IMGF000045_0003_TABLE
Patent Text Reader

Abstract

Resistant potato starch (RPS) constipation and - - - - - -L- - 1- -4- -3- - - -3- -3- -7-.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MODULATION OF THE FECAL METABOLOME TO REDUCE DIARRHEA USING RESISTANT STARCH SUPPLEMENTATION BACKGROUND OF THE INVENTION

[0002] Constipation and diarrhea are common afflictions in otherwise healthy people, and are symptoms associated with myriad health concerns. Changes in stool form are primarily influenced by factors affecting intestinal water transport and motility. Microbial activities are known to influence intestinal watertransportand subsequent stool form, especially in the context of diarrhea. For example, Vibrio cholerae, the bacteria responsible for cholera, produces an enterotoxin that stimulates fluid secretion in the intestines, causing diarrhea [1]. Microbiota also contribute to constipation-associated bowel movement scores, but this appears to be due to influences on intestinal transit time. For example, individuals with intestinal methanogen overgrowth, characterized by excessive luminal levels of methanogenic archaea, have a higher incidence and severity of constipation and lower incidence and severity of diarrhea than controls [2], which is attributed to the transit slowing effects of methane [3].

[0003] Macronutrient intake also strongly influences stool form, especially the quantity of dietary fibre in the diet. Low levels of dietary fibre-containing foods are associated with higher incidence of constipation [4] and dietary supplementation with fibre can improve constipation [5]. Psyllium husk from certain species of Plantago is one of a handful of dietary fibres that provides benefit to both those suffering from constipation and those suffering from diarrhea. This is due to the abundant mucilage content, which binds water to reduce diarrhea [6] and increases bulk to relieve constipation [7]. Notably, psyllium is not appreciably fermented by gut microbiota [8], consistent with these benefits arising from the water binding effects of the mucilaginous content.

[0004] Prebiotics, which constitute substrates that are selectively utilized by host microorganisms conferring a health benefit [9], include forms of dietary fibre and other substances that have demonstrated this property in at least on clinical study

[0010] . Studies examining the effect of soluble prebiotics on constipation tend to reveal benefits, attributed to increases in beneficial bacteria abundance and short chain fatty acid production, but also likely due to osmotic effects that draw water into the intestines to soften stools

[0011] . However, these same properties mean that soluble prebiotics can exacerbate diarrhea and dietary restriction of these substances can improve diarrhea symptoms

[0012] .Resistant potato starch (RPS) is a prebiotic insoluble fibre that was shown to increase abundance of Bifidobacterium and Akkermansia bacteria, and reduce the incidence of both constipation- and diarrhea-associated bowel movements

[0013] . Despite these genera normally being associated with host health, changes in the abundance of abundance of Bifidobacterium and Akkermansia were not correlated with improvements in bowel movement scores using a scoring system that accounts for perceived urgency to defecate

[0014] . While changes in constipation- and diarrhea-associated bowel movements were correlated with changes in gut microbiota, the effects were heterogenous and the taxonomic groups were not well-characterized in the context of irritable bowel syndrome (IBS). We hypothesized that changes in bacterial activity, rather than abundance, might be responsible for RPS-induced stool form improvements. We therefore evaluated correlations between changes in stool metabolites and changes in the frequency of both constipation- and diarrhea-associated bowel movements to elucidate the mechanism of action by which RPS exerts these prebiotic benefits.

[0005] SUMMARY OF THE INVENTION

[0006] According to an aspect of the invention, there is provided a method of decreasing fecal phenylethylamine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0007] In another aspect of the inventions, there is provided a method of decreasing fecal 3,5-dihydrobenzoic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0008] In another aspect of the inventions, there is provided a method of decreasing fecal beta aminobutyric acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0009] In another aspect of the inventions, there is provided a method of decreasing fecal thiamine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0010] In another aspect of the inventions, there is provided a method of increasing fecal cystine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.In another aspect of the inventions, there is provided a method of increasing fecal N1 -acetyl putrescine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0011] In another aspect of the inventions, there is provided a method of increasing fecal 3-hydroxyhexadecanoylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0012] In another aspect of the inventions, there is provided a method of increasing fecal 3-methylcrotonyl-L-carnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0013] In another aspect of the inventions, there is provided a method of increasing fecal orotic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0014] In another aspect of the inventions, there is provided a method of increasing fecal propionylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0015] In another aspect of the inventions, there is provided a method of increasing fecal maltose levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0016] In another aspect of the inventions, there is provided a method of increasing fecal lactose levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0017] In another aspect of the inventions, there is provided a method of increasing fecal 2-methylbutyrylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0018] In another aspect of the inventions, there is provided a method of increasing fecal phenyllactic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0019] In some embodiments of the invention, the dosage regimen is administering resistant potato starch daily fora period of 1-12 weeks, for example, 2-12 weeks, 3-12 weeks, 4-12 weeks, 5-12 weeks, 6-12 weeks, 7-12 weeks, 8-12 weeks, 9-12 weeks, 10-12 weeks, 11-12 weeks, 1-11 weeks,1-10 weeks, 1-9 weeks, 1-8 weeks, 1-7 weeks, 1-6 weeks, 2-6 weeks, 2-7 weeks, 2-8 weeks, 2-9 weeks, 2-10 weeks, 2-11 weeks, 3-6 weeks, 3-7 weeks, 3-8 weeks, 3-9 weeks, 3-10 weeks, 3-11 weeks or 3-12 weeks. In this context, “daily” does not necessarily mean “everyday”, but may mean for example 19 out of 20 days, 9 out of 10 days, 17 out of 20 days or 8 out of 10 days.

[0020] As discussed herein, the effective amount may be, for example, 0.5 to 40g, or 0.5 to 30g, or 0.5 to 7g, or 0.5 to 3.5g of resistant starch.

[0021] BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1. Among the fecal metabolites that were significantly correlated with changes in diarrhea in RPS consuming participants, only levels of 3-hydroxyhexadecanoylcarnitine (G) were different between treatment groups. (Two-way ANOVA, mean + / - SEM)

[0023] Figure 2. Among the fecal metabolites that were positively correlated with changes in diarrhea in RPS-consuming individuals, diarrhea non-responders (light grey bars) experienced changes in fecal metabolite that significantly differed from diarrhea responders (dark grey bars) for phenylethylamine (A), 3,5-dihydrobenzoic acid (B), beta-aminobutyric acid (C), and thiamine (D). (Two-way ANOVA, mean + / - SEM)

[0024] Figure 3. Among the fecal metabolites that were negatively correlated with changes in diarrhea in RPS-consuming individuals, diarrhea non-responders (light grey bars) experienced changes in fecal metabolite that significantly differed from diarrhea responders (dark grey bars) for cystine (A), 3-hydroxyhexadecanoylcarnitine (C), 3-methylcrotonylcarnitine (D), orotic acid (E), propionylcarnitine (F), maltose (G), and lactose (H). Changes in these metabolites did not distinguish non-responders from responders in the placebo treatment group. (Two-way ANOVA, mean + / - SEM)

[0025] Figure 4. Diarrhea-correlated metabolites that differed between diarrhea non-responders and responders at weeks 1 and 4 were associated with serotonin (A, B), lactic acid (C, D), cysteine (E, F), and taurine (G, H). Levels of serotonin (A), cysteine (C), and taurine (D) differed between treatment groups. Diarrhea non-responders (light grey bars) experienced changes in fecal metabolite that significantly differed from diarrhea responders (dark grey bars) for serotonin (B) and cysteine (F). (Two-way ANOVA, mean + / - SEM)

[0026] Figure 5. Among the fecal metabolites that were significantly correlated with changes in constipation in RPS consuming participants using the revised 6 day period for Week 1, levels ofimidazole propionic acid (D), 1-methyl-4-imidazoleacetic acid (E), and linoleylcarnitine (I) were different between treatment groups. (Two-way ANOVA, mean + / - SEM)

[0027] Figure 6. Constipation non-responders (light grey bars) experienced changes in fecal metabolite that significantly differed from diarrhea responders (dark grey bars) for none of the fecal metabolites that were positively correlated with changes in constipation in RPS-consuming individuals using the revised 6 day period for Week 1. (Two-way ANOVA, mean + / - SEM) Figure 7. Among the fecal metabolites that were significantly correlated with changes in diarrhea in RPS consuming participants using the revised 6 day period for Week 1 , levels of palmitoyl carnitine (B) and myristoylcarnitine (C) were different between treatment groups. (Two-way ANOVA, mean + / - SEM)

[0028] Figure 8. Diarrhea non-responders (light grey bars) experienced changes in fecal metabolite that significantly differed from diarrhea responders (dark grey bars) for 3-hydroxyaspartic acid (E), myristoylcarnitine (G), chenodeoxycholic acid (J), and phosphocholine (K) in RPS-consuming individuals using the revised 6 day period for Week 1. (Two-way ANOVA, mean + / - SEM) DESCRIPTION OFTHE PREFERRED EMBODIMENTS

[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

[0030] As used herein, “treating” in all of its grammatical forms does not necessarily require the “curing” of the disease, disorder, episode, occurrence or incident, but rather refers to at least one of the following: lessening the frequency and / or duration and / or severity of feelings of illness and / or one or more symptoms associated with the disease, disorder, episode, occurrence or incident.

[0031] As used herein, “an individual”, for example, “an individual in need of such treatment”, refers to an animal, for example, a livestock animal, for example, a cow, pig, chicken or other animal raised forfood production or a domestic animal raised as a pet or a human.

[0032] For example, individuals who had diarrhea-associated (type 7) BMs at least once or at least twice in a two week period or who experienced type 7 diarrhea-associated BMs as at least 5%, at least 6%, at least 7%, at least 8%, at least 9% or at least 10% of all BMs during a two week period,for example, during the baseline / run-in period (before treatment) will be treated in that there will be a reduction in the frequency of type 7 BMs over a similar period during and / or following treatment with or consumption of RPS, as discussed herein.

[0033] The resistant potato starch (RPS) used in this study contains >60% RS by weight on an “as is” basis (AOAC 2002.02)

[0015]

[0016] (Solnul®; MSP Starch Products Inc., Carberry, MB, Canada). A fully high-amylopectin corn starch, containing no detectable levels of RS

[0015]

[0016] and no microbiome modulating properties

[0017] , was used as the placebo (Amioca™TF; Ingredion, Brampton, ON, Canada), and has been previously shown to not affect the gut microbiota

[0036] . While Solnul®, which contains 60% RS by AOAC 2002.02 methods, is used in the trials and experiments discussed herein, it is important to note that as discussed herein, another suitable unmodified potato starch or resistant potato starch (RS type 2) comprising at least 50% resistant starch or at least 55% resistant starch or at least 60% resistant starch on an ‘as is’ basis and meeting USP criteria for potato starch may be used. Placebo and RPS products were packaged in identical single-serving packets and labeled according to randomization codes generated by Nutrasource Pharmaceutical and Nutraceutical Services (Guelph, ON, Canada) staff not involved in study data collection to ensure blinding, as previously described

[0013] .

[0034] As discussed herein, we demonstrate that supplementation with resistant potato starch (RPS) influences the fecal level of metabolites correlated with improvements in diarrhea.

[0035] Specifically, RPS decreased fecal levels of phenylethylamine, 3,5-dihydroxybenzoic acid, betaaminobutyric acid, and thiamine while increasing levels of cystine, 3-hydroxyhexadecanoylcarnitine, 3-methylcrotonylcarnitine, orotic acid, propionylcarnitine, maltose, and lactose in people experiencing decreases in diarrhea.

[0036] Healthy adults aged 18-69 years of age with a body mass index of 18.0 to 34.9 kg / m2 were recruited and enrolled in the study. Exclusion criteria included diseases or conditions that affect the gastrointestinal (Gl) system, diagnosis of irritable bowel syndrome, dyspepsia, significant Gl symptoms, family history of peptic ulcers, colorectal cancer, or inflammatory bowel disease, or conditions that restrict the diet, such as lactose intolerance or gluten intolerance. Eligible participants agreed to not consume any vitamins, minerals, or dietary supplements 14 days prior to the randomization visit until the completion of the study. Participants were counseled to follow their habitual diet throughout the study period and no changes in dietary intake were observed

[0014] .The study was a randomized, double-blind, placebo-controlled, parallel-armed clinical trial that was designed to evaluate the effect of daily 3.5 g of RPS (containing 3.5 g of RPS and 3.5 g placebo, with 7 g total carbohydrates), 7 g of RPS, and 7 g of placebo for 4 weeks on fecal bacteria composition and bowel movement characteristics. Forty-eight participants completed the study protocol for the 3.5 g RPS (n = 24) and placebo (n = 24) arms. Stool samples were collected at baseline, 1-weekand 4-weeks of supplementation and analyzed by targeted metabolomics to quantify metabolite levels. Only the impact of 3.5 g RPS supplementation on microbially-influenced stool metabolites was assessed relative to changes in constipation- and diarrhea-associated stool form.

[0037] Participants scored their bowel movements using the Bristol Stool Form Scale (BSFS), where Type 1 = constipation with hard, round stools, Type 2 = lumpy and sausage-like, Types 3 and 4 are soft, easily passed ‘normal’ stools, Type 5 = soft blobs with clear-cut edges, Type 6 = mushy consistency with ragged edges, and Type 7 = watery diarrhea

[0018] . Constipation scores were derived from bowel movements with BSFS Types 1 or 2 and diarrhea scores were derived from bowel movements with BSFS Type 7. The frequency of constipation- and diarrhea-associated bowel movements was determined during the run-in period (~ 14 days prior to intervention; Baseline), during the first week (Week 1), and during the last week (Week 4) of the intervention period.

[0038] Changes in constipation- and diarrhea-associated bowel movements were determined by subtracting the baseline value from eitherweek 1 orweek4 value.

[0039] Each stool sample suspended in an OMNImet-Gut collection kit had been stored at -80 °C after receipt. For sample preparation, the content of each kit was completely transferred to a preweighed 5-mL safe-lock Eppendorf tube. The volume of each sample in the tube was estimated and then brought to an equal volume of 2 mLwith 95% HPLC-grade ethanol. Two 4-mm I.D. metal beads were added to each tube. The samples were homogenized on an MM 400 mill mixer at 25 Hz for 5 min, followed by ultra-sonication in an ice-water bath for 3 min. The samples were centrifuged at 15,000 gand 10 °C for 10 min in an Eppendorf 5425R centrifuge. The clear supernatants were collected into another set of 5-mL safe-lock Eppendorf tubes and stored at -80 °C for the following metabolomic assays. For the stool material pelleted in the original 5-mL tubes, 2 mL aliquots of water were added and then frozen at -80 °C overnight and subsequently lyophilized to dryness. The tubes were reweighed. The weight of the dry mass of each stool sample was calculated and used to normalize the final results for the different metabolites.The assay of amino acid and amine-type metabolites basically used the same method described for human serum samples of the same study in a publication

[0019] . 20 pL aliquots of the fecal metabolite supernatants were dried in a nitrogen evaporator. The dried residues were dissolved in 20 pL of an isotope-labeling internal standard (IS) solution. Along with the sample preparation, serially diluted calibration solutions containing all the measured metabolites were prepared in the same IS solution. 20 pL aliquots of the sample solutions and 20 pL aliquots of the calibrations were mixed with 60 pL of 10-mM dansyl chloride solution and 20 pL of 100-mM borate buffer at pH 9. The mixtures were incubated at 40 °C for 30 min. 5-pL aliquots of the resultant sample and calibration solutions were injected to run LC-MRM / MS on LC-MS / MS system composed of an Agilent 1290 UHPLC and an Agilent 6495B triple-quadrupole mass spectrometer with positive-ion detection, using the LC and MRM / MS operating parameters described in the publication

[0019] .

[0040] The assay of low-MW sugars and organic acids used a chemical derivatization - LC-MRM / MS method that was previously described

[0020]

[0021] , with necessary modifications. In short, a standard solution containing standard substances of low-MW sugars and organic acids was prepared and then serially diluted in 95% HPLC-grade ethanol. 20 pL of each calibration solution or 20 pL of the clear extractant from each stool sample was mixed with 20 pL of an internal standard solution of 6 isotope-labeled sugars

[0020] and 9 isotope-labeled organic acids

[0021] , 40 pL of 200-mM 3-nitrophenylhydrazine solution and 40 pL of 150-mM EDC-6% pyridine solution. The mixtures were incubated at 60 °C for 60 min. After cooling, 5 pL aliquots of the resultant sample and calibration solutions were injected to run LC-MRM / MS on LC-MS / MS system composed of an Agilent 1290 UHPLC and an Agilent 6495B triple-quadrupole mass spectrometer with positive-ion detection, using the LC and MRM / MS operating parameters described in the publications.

[0041] Assay of bile acids in stool used an LC-MRM / MS method described in a publication that previously described the methods for bile acid analysis in serum

[0022] . Briefly, 20 pL of the clear extractant from each stool sample was mixed with 180 pL of an IS solution of 14 isotope-labeled bile acids. Along with the sample solution preparation, serially diluted calibrations of all the measured bile acids were prepared with their standard substances in the same IS solution. 10 pL aliquots of the resultant sample and calibration solutions were injected to run LC-MRM / MS on an LC-MS / MS system composed of an Agilent 1290 UHPLC and an Agilent 6495B triple-quadrupolemass spectrometer with negative-ion detection, using the LC and MRM / MS operating parameters described in the publication.

[0042] To assay the other polar metabolites, 100 pL of the clear extractant from each stool sample was dried in a nitrogen evaporator. The dried residues were dissolved in 100 pL of an IS solution containing 40 isotope-labeled internal standards in 10% methanol. Along with the sample solution preparation, serially diluted calibration solutions containing standard substances of all the measured metabolites were prepared in the same IS solution. 6-pL aliquots of the resultant sample and calibration solutions were injected into a Waters HSST3 column (2.1x100 mm, 1.8 pm) to run LC-MRM / MS on an LC-MS / MS system composed of an Agilent 1290 UHPLC and an Agilent 6495B triple-quadrupole mass spectrometer with positive-ion detection. A mobile phase composed of a 2-mM perfluorobutanoic acid solution and acetonitrile was used for binary-solvent gradient elution under optimized chromatographic separation and mass spectrometric operating conditions.

[0043] The above quantitation was performed with internal standard calibration. Linearly regressed calibration curves of individual metabolites were constructed with the data acquired from injecting the calibration solutions in each set of UPLC-MRM / MS runs. Molar concentrations of the compounds detected in the stool were calculated by interpolating the calibration curves of individual metabolites with the analyte-to-IS peak area ratios measured from injecting the sample solutions.

[0044] Changes in metabolite levels were calculated by subtracting the baseline level from either week 1 or week 4 levels. Changes in constipation- (BSC Type 1 or 2) and diarrhea-associated (BSC Type 7) bowel movements were calculated by subtracting the baseline value from either week 1 or week 4 value. Notably, the first iteration of analysis included all (8 days) bowel movement scores for week 1 and six days of bowel movement scores for week 4, roughly corresponding with previous analysis

[0013] . In the second iteration of analysis, the first two days of the week 1 period were omitted for two reasons: First, very little effect from the gut microbiome is expected to occur in the 48 hour period after dosing is initiated and, second, the revised 6 day duration matches the length of time during which week 4 bowel movements were collected. Pearson correlation coefficients (r) were generated to assess associations between changes in stool metabolites and changes in constipation or changes in diarrhea stools.Mean changes in metabolite levels were then compared between the placebo and RPS using two-way ANOVAto assess the overall effect of treatment. To account for multiple comparisons, positive false discovery rate (pFDR) adjusted q values were generated using the Benjamini Hochberg method

[0023] for Pearson correlations. All statistical analyses were performed using Excel (Version 2409; Microsoft Excel, Redmond, WA, USA). Statistical significance was considered at p < 0.05 or q < 0.05 when multiple comparisons were performed.

[0045] Pearson correlation analysis was performed comparing changes in constipated bowel movements (Types 1 or 2 on the BSFS) to changes in stool metabolites at week 1 (8 days) and week 4 time points. Metabolite correlations were ranked by p value using the Benjamini-Hochberg method, with correlations having a p value less than the q value being significant. However, no metabolite-constipation correlations were significant after correction during the first iteration of analysis (data not shown).

[0046] Pearson correlation analysis was performed comparing changes in diarrhea bowel movements (Type 7 on the BSFS) to changes in stool metabolites at the week 1 (8 days) and week 4 time points. Metabolite correlations from the first iteration of analysis were ranked by p value using the Benjamini-Hochberg method, and those with a p value less than the q value were considered significant (Table 1). Changes in phenylethylamine, 3,5-dihydroxybenzoic acid (3,5-DHBA), p-aminobutyric acid, and thiamine were positively correlated with changes in diarrhea (Table 1), indicating that reductions in these metabolite levels accompanied reductions in diarrhea-associated bowel movements. Changes in cystine, N1 -acetyl putrescine, 3-hydroxyhexadecanoylcarnitine, 3-methylcrotonyl-L-carnitine, orotic acid, propionylcarnitine, maltose, lactose, 2-methylbutyrylcarnitine, and phenyllactic acid were negatively correlated with changes in diarrhea (Table 1), indicating that increases in these metabolite levels accompanied reductions in diarrhea bowel movements.

[0047] Constipation and diarrhea can be driven by too little or too much fecal water, respectively. Notably, changes in several metabolites correlated with diarrhea tended (p s 0.1) to be inversely correlated with changes in constipation, including cystine, 3,5-DHBA, and N1 -acetyl putrescine tended to be inversely correlated with changes in constipation (Table 1 ).

[0048] Among the metabolites correlated with changes in diarrhea, only levels of 3-hydroxyhexadecanoylcarnitine were significantly different between treatment groups (Figure 1 G),while levels of 3,5-DHBA (Figure 1 B), 3-methylcrotonyl-L-carnitine (Figure 1 H), and 2-methylbutyrylcarnitine (Figure 1 M) tended to be different.

[0049] Six participants in the RPS treatment group experienced a total of 11 diarrheal (Type 7) stools during the run-in period, all of whom improved

[0013] . In the placebo group, 4 participants displayed reductions in the incidence of diarrheal stools. We therefore asked whether individuals displaying improvements in diarrhea (responders) might differfrom individuals not displaying improvements in diarrhea (non-Responders) with respect to changes in diarrhea-associated metabolites in both the placebo and RPS treatment groups at week 1 and week 4 timepoints. In the RPS treatment group, levels of phenylethylamine (Figure 2A), 3,5-DHBA (Figure 2B), p-aminobutyric acid (Figure 2C), and thiamine (Figure 2D) were decreased in responders. Levels of cystine (Figure 3A), 3-hydroxyhexadecanoylcarnitine (Figure 3C), 3-methylcrotonyl-L-carnitine (Figure 3D), orotic acid (Figure 3E), propionylcarnitine (Figure 3F), maltose (Figure 3G), and lactose (Figure 3H) were increased in responders in the RPS treatment group. There were no differences between responders and non-responders in changes in any diarrhea-associated metabolites in the placebo group (Figures 2 and 3).

[0050] We next reanalyzed the correlations between changes in metabolite levels and changes in constipation using the revised week 1 constipation recordings, which consisted of the final 6 days of the week 1 time period. Pearson correlation analysis was performed comparing changes in constipated bowel movements (Types 1 or 2 on the BSFS) to changes in stool metabolites at week 1 (6 days) and week 4 time points. Metabolite correlations were ranked by p value using the Benjamini-Hochberg method, with correlations having a p value less than the q value being significant (Table 6). Changes in FA(16:0-OH), lithocholic acid-3-sulfate, deoxycholic acid-3-sulfate, imidazole propionic acid, 1-methyl-4-i midazoleacetic acid, hyodeoxycholic acid-3-sulfate, cholic acid-7-sulfate, FA(22:5), and linoleylcarnitine were positively correlated with changes in constipation indicating that reductions in these metabolite levels accompanied reductions in constipation-associated bowel movements. Levels of imidazolepropionic acid (Figure 5D), 1-methyl-4-imidazoleacetic acid (Figure 5E), and linoleylcarnitine (Figure 5I) differed between RPS and placebo treatment groups, but the levels of these metabolites did not differ between constipation responders and non-responders in either placebo or RPS treatment groups (Figure 6).

[0051] Correlations between changes in metabolite levels and changes in diarrhea were reanalyzed using the revised week 1 constipation recordings, which consisted of the final 6 days ofthe week 1 time period. Pearson correlation analysis was performed comparing changes in constipated bowel movements (Types 7 on the BSFS) to changes in stool metabolites at week 1 (6 days) and week 4 time points. Metabolite correlations were ranked by p value using the Benjamini-Hochberg method, with correlations having a p value less than the q value being significant (Table 7). While many diarrhea-correlated metabolites were shared among the initial and reanalysis data sets, 1-methyl-4-imidazoleacetic acid, imidazolepropionic acid, linoleylcarnitine, hyodeoxycholic acid-3-sulfate, 3-hydroxyaspartic acid, palmitoylcarnitine, myristoylcarnitine, oleylcarnitine, ursodeoxycholic acid, chenodeoxycholic acid, phosphocholine, and isobutyrylcarnitine were not previously identified. The effect of RPS versus placebo on levels of 1-methyl-4-imidazoleacetic acid, imidazolepropionic acid, linoleylcarnitine, and hyodeoxycholic acid-3-sulfate was already reported due to these metabolites being correlated with changes in constipation (Figure 5). Levels of palmitoylcarnitine (Figure 7B) and myristoylcarnitine (Figure 7C) differed between RPS and placebo treatments. Among these diarrhea-correlated metabolites, levels of 3-hydroxyaspartic acid (Figure 8E), myristoylcarnitine (Figure 8G), chenodeoxycholic acid (Figure 8J), and phosphocholine (Figure 8K) significantly differentiated non-responders from responders in the RPS treatment group. In the placebo group, decreases in hyodeoxycholic acid-3-sulfate (Figure 8D) significantly differentiated non-responders from responders.

[0052] Specifically, in the RPS treatment group, the diarrhea responders were anyone who had a type 7 bowel movement during the study and because all participants experiencing a type 7 bowel movement improved at week4, all are considered responders. For diarrhea analysis in the placebo group, participants were grouped together as those who experienced reductions in type 7 BMs (responders) and those who did not (non-responders). For constipation correlation analysis in both the RPS and placebo treatment groups, participants were considered responders if they experienced a reduction in constipation-associated bowel movement (Type 1 or 2) frequency at week 4.

[0053] We next examined metabolites known to influence or be influenced by the diarrhea-associated metabolites in Table 1 that displayed differences between diarrhea responders and non-responders at weeks 1 and 4 (Figures 2 and 3). In a rodent model of IBS-D, Ruminococcus gnavus converted phenylalanine to phenylethylamine, which activated trace amine-associated receptor 1 (TAAR1) on enterochromaffin cells to secrete serotonin and promote accelerated gastrointestinal transit and colonic secretion

[0024] . Changes in serotonin were correlated with changes in diarrhea inthe RPS treatment group (r = 0.291 ; p = 0.04) but were not significant after correction for multiple testing. Levels of serotonin were higher in the placebo group than the RPS group (Figure 4A), and changes in serotonin levels differentiated diarrhea non-responders from responders in both the placebo and RPS treatment groups (Figure 4B). In the RPS treatment group, serotonin levels rose in diarrhea non-responders (Figure 4B), suggesting that changes in serotonin might influence constipation as well. However, changes in serotonin were not significantly correlated with changes in constipation (r = 0.131; p = 0.4). Like phenylethylamine, the tryptophan derivative tryptamine and the tyrosine derivative tyramine stimulate serotonin release

[0024]

[0025] . However, changes in neither tryptamine (r = 0.033; p = 0.8) nor tyramine (r = 0.036; p = 0.8) were correlated with changes in diarrhea in the RPS treatment group.

[0054] Pearson analysis can be sensitive to outliers, where a single data point can drive significance. We therefore performed Spearman correlation analysis comparing ranked changes in constipation and diarrhea to ranked changes in fecal metabolites using the revised 6 day values for the week 1 time point. There were no significant Spearman correlations between changes in constipation or changes in diarrhea in the RPS group. However, incidences of constipation and diarrhea affected only 14 and 7 participants, respectively, meaning that many participants in the RPS group did not experience a change in either constipation or diarrhea. We therefore performed Spearman correlation analysis between changes in constipation and changes in stool metabolites in participants experiencingType 1 or 2 stools. In the RPS treatment group, changes in glycodeoxycholic acid-3-sulfate (p = 0.632, p = 0.0002, q = 0.06143127) and caffeic acid (p = 0.614, p = 0.0003, q = 0.06143127) were positively correlated with changes in constipation but changes in these metabolites were not correlated with changes in constipation in the placebo group (q > 0.1 ). We similarly performed Spearman correlation analysis between changes in diarrhea and changes in stool metabolites in participants experiencingType 7 stools. In the RPS treatment group, changes in N1 -acetyl putrescine (p = -0.855, p = 0.0001 , q = 0.029323138), FA(24:6) (p = 0.804, p = 0.0005, q = 0.05071972), indole-3-carbinol (p = 0.795, p = 0.0007, q = 0.05071972), indole-3-aldehyde (p = 0.791 , p = 0.0008, q = 0.05071972), putrescine (p = -0.791 , p = 0.0008, q = 0.05071972), and 3,5-dihydroxybenzoic acid (p = 0.754, p = 0.002, q = 0.093967978) were correlated with changes in diarrhea but changes in these metabolites were not correlated with changes in diarrhea in the placebo group (q > 0.1).3,5-dihydroxybenzoic acid acts through the lactate receptor hydroxycarboxylic acid receptor 1 (HCAR1; also known as GPR81) producing various effects in different tissues

[0026] .

[0055] Changes in lactate tended to be inversely correlated with changes in diarrhea in the RPS treatment group (Table 2) but the relationship was opposite the effect observed for 3,5-DHBA. Levels of lactic acid were not different between treatment groups (Figure 4C), and changes in lactic acid did not distinguish between diarrhea responders and non-responders in either treatment group (Figure 4D). Changes in the levels of the related metabolites protocatechuic acid and 4-hydroxybenzoic acid were not correlated with changes in diarrhea (Table 2).

[0056] Cystine is the oxidized disulfide derivative of two cysteine amino acids, suggesting that cysteine levels might also be correlated with changes in diarrhea. Indeed, changes in cysteine were correlated with changes in diarrhea in the RPS treatment group (Table 3) but were not significant after correction for multiple testing. Levels were different between treatment groups (Figure 4E), and changes in cystine distinguished between diarrhea responders and non-responders in the RPS group but not those consuming the placebo (Figure 4F). Changes in the levels of other metabolites involved in cysteine metabolism were not correlated with changes in diarrhea (Table 3).

[0057] While p-aminobutyric acid is notwell characterized outside of plants, in vitro studies show that p-aminobutyric acid has concentration-dependent effects on the human alpha 1 glycine receptor, with low concentrations competitively inhibiting a glycine response and higher concentrations inducing significant membrane currents

[0027] . Except for taurine, changes in the levels of glycine and other glycine receptor agonists were not correlated with changes in diarrhea in the RPS treatment group (Table 4). Taurine levels were different between treatment groups (Figure 4G) and while taurine levels tended to differ between diarrhea responders and non-responders in the RPS treatment group (Figure 4H), this effect was not significant. Levels of p-aminobutyric acid are also known to influence y-aminobutyric acid transport in an intestinal cell model

[0028] . However, changes in the levels of y-aminobutyric acid and related metabolites known to influence gastric acid secretion

[0029] were not correlated with changes in diarrhea in the RPS treatment group (Table 5). To our knowledge, there are no metabolites known to influence or be influenced by changes in fecal thiamine levels in the context of diarrhea.

[0058] Reanalysis of the data set using revised 6 day values for the week 1 time point identified significant correlations between changes in constipation and changes in fecal metabolites, as well as correlations between changes in diarrhea and changes in metabolites not identified in the initialanalysis. None of the constipation-correlated metabolites differentiated constipation responders from non-responders (Figure 6). However, levels of 3-hydroxyaspartic acid (Figure 8E), myristoylcarnitine (Figure 8G), chenodeoxycholic acid (Figure 8J), and phosphocholine (Figure 8K) were higher in diarrhea responders compared to non-responders. We therefore examined metabolites known to influence or be influenced by these diarrhea-associated metabolites. Growth of Escherichia coli and Leuconostoc mesenteroides is inhibited by beta-hydroxyaspartic acid in vitro

[0030] , an effect linked to antimetabolite activity that disrupts the aspartate-to-threonine synthesis pathway

[0031] . We therefore examined levels of animo acids involved in this pathway but found no correlations between changes in these amino acids and changes in diarrhea in the RPS treatment group (Table 8). In addition to acting as an antibiotic

[0032] , 3-hydroxyaspartic acid also potentiates and prolongs the activation of glutamatergic enteric neurons, which influence intestinal motility

[0033] . However, diarrhea changes were not correlated with changes in glutamic acid in the RPS treatment group (Table 8).

[0059] Elevated bile acids can cause bile acid diarrhea

[0034] , but the relationship between discrete bile acids and diarrhea is not straightforward. Chenodeoxycholic acid, which is elevated in diarrhea-responders in the RPS treatment group (Figure 8J), induces water absorption at low concentrations (1-3 mM) but promotes water secretion at high concentrations (5-10 mM)

[0035] . In the same study, cholic acid promoted water absorption at all concentrations while deoxycholic acid only promoted water absorption at the lowest (1 mM) concentration, and favored secretion at higher concentrations. Given that changes in bile acids were correlated with changes in both constipation (Table 6) and diarrhea (Table 7), we compared correlations between these changes and changes in unconjugated bile acids (Table 9), conjugated bile acids (Table 10), and sulfated or glucuronidated bile acids (Table 11). Sulfated bile acids were over- re presented among bile acids significantly correlated (uncorrected p < 0.05) with changes in constipation (8 / 10) compared to uncorrelated (p > 0.05) bile acids (14 / 61; Fisher’s Exact test p = 0.0009). Sulfated bile acids were not over-represented among bile acids significantly correlated (uncorrected p < 0.05) with changes in diarrhea (7 / 18) compared to uncorrelated (p > 0.05) bile acids (15 / 52; Fisher’s Exact test p = 0.6). Changes in deoxycholic acid-3-sulfate, lithocholic acid-3-sulfate, hyodeoxycholic acid-3-sulfate, cholic acid-7-sulfate, taurolithocholic acid, isolithocholic acid-3-sulfate, and chenodeoxycholic acid-3-sulfate were significantly (uncorrected p < 0.05) correlated with both changes in constipation and changes in diarrhea. These data suggest that bile acid sulfation acts as a general mechanism to balance water abundance in the colon, which influences both constipation anddiarrhea. This is consistent with the general understanding that sulfated bile acids are more water soluble, are absorbed poorly by the intestines, and are generally eliminated in the urine

[0036] . While not influencing intestinal secretion directly, sulfated bile acids appear to prevent intestinal secretion induced by non-sulfated bile acids at high (>5 mM) doses in a rat perfusion model

[0037] . Sulfated bile acids are elevated in children with functional constipation, an effect that was driven by 6 constipated patients displaying chenodeoxycholic acid-3-sulfate as the predominant fecal bile acid

[0038] . Sulfation of bile acids occurs primarily in liver

[0039] and intestinal cells to a lesser degree

[0040] , while bacteria possessing sulfatase activity can decrease the abundance of sulfated bile acids

[0041] . Therefore, RPS might be acting locally in the intestines to influence bile acid sulfation, systemically to control activities in the liver, or acting via combined effects. We reasoned that if RPS was influencing host sulfation in the liver, systemic levels of sulfated bile acids should also be correlated with changes in constipation and diarrhea. Changes in serum sulfated bile acids were not significantly correlated with changes in constipation or diarrhea (Table 12), suggesting that RPS is not exerting a global effect on bile acid sulfation. While not wishing to be held to a particular hypothesis or mechanism of action, RPS appears to act locally, either by influencing the activity of intestinal sulfotransferases or sulfate removing activity of bacteria in the gut.

[0060] In addition to the complex interplay between host physiology and bacterial activity, expression of sulfotransferases catalyzing the synthesis of sulfated bile acids appears to be heavily influenced by sex

[0042] . This complexity in sulfated bile acid metabolism potentially explains why changes in sulfated bile acids were highly variable (see Figures 6B, 6C, 6F, 6G, and 8D), and suggests that the effects of discrete sulfated bile acids are likely playing conserved roles in different individuals.

[0061] Phosphocholine levels were significantly elevated in piglets with diarrhea, as were choline levels, an effect that was attributed to reductions in Candida tropicalis, an Ascomycete that normally consumes phosphocholine for energy

[0043] . While this effect was the opposite to the observed relationship between phosphocholine and diarrhea in RPS consuming participants, we tested whether changes in diarrhea were correlated with changes in choline, but found no correlation (r = 0.096; p = 0.5). Alkaline sphingomyelinase cleaves phosphocholine from a number of important signaling molecules, including sphingomyelin, lysophosphatidylcholine, and plateletactivating factor

[0044] , but none of these substances or their metabolites were captured in ouranalysis, preventing further investigation of these metabolites in the context of constipation or diarrhea.

[0062] Changes in the levels of 14 fecal metabolites were correlated with changes in diarrhea in participants consuming RPS while no correlations were identified with changes in constipation in the initial analysis. Abundance of these metabolites tended to be similar between placebo and RPS treatment groups. However, decreases in phenylethylamine, 3,5-DHBA, p-hydroxybutyric acid, and thiamine differentiated diarrhea responders from non-responders in the RPS group. Similarly, increases in cystine, 3-hydroxyhexadecanoylcarnitine, 3-methylcrotonylcarnitine, orotic acid, propionylcarnitine, maltose, and lactose differentiated diarrhea responders from non-responders in the RPS group. Resistant potato starch induced fecal metabolite changes that were connected to other fecal metabolites previously connected to diarrhea, including serotonin, cysteine, and taurine. Upon reanalysis focusing on bowel movements documented during the last 6 days of week 1, 12 additional metabolites were found to be significantly inversely correlated with changes in diarrhea in the RPS treatment group, including 1-methyl-4-imidazoleacetic acid, imidazole propionic acid, linoleylcarnitine, hyodeoxycholic acid-3-sulfate, 3-hydroxyaspartice acid, palmitoylcarnitine, myristoylcarnitine, oleylcarnitine, ursodeoxycholic acid, chenodeoxycholic acid, phosphocholine, and isobutyrylcarnitine. Reanalysis also revealed 9 metabolites that were significantly positively correlated with changes in constipation in the RPS treatment group, including FA(16:0-OH), lithocholic acid-3-sulfate, deoxycholic acid-3-sulfate, imidazolepropionic acid, 1-methyl-4-imidazoleacetic acid, hyodeoxycholic acid-3-sulfate, cholic acid-7-sulfate, FA(22:5), and linoleylcarnitine. Remarkably, 1-methyl-4-imidazoleacetic acid, imidazolepropionic acid, linoleylcarnitine, and hyodeoxycholic acid-3-sulfate were positively correlated with changes in constipation and negatively correlated with changes in diarrhea, suggesting that control of these and related metabolites could regulate stool form in a dynamic fashion.

[0063] It is reasonable to expect that outlier data points represent real effects because data sets representing the human gut microbiome or human fecal metabolome are heterogeneous. For example, reductions in the diarrhea-causing fecal metabolite phenylethylamine were correlated with changes in diarrhea, which were largely driven by one responder. Rather than attributing this outlier to technical error, it is possible that -despite being screened for digestive disorders- this individual had high baseline levels of phenylethylamine and the reduction of this metabolite via RPS administration led to improvements in diarrhea. The lack of correlation between phenylethylamineand diarrhea in other participants consuming RPS is likely because, below a threshold level, this metabolite has no effect on stool form.

[0064] We subsequently undertook Spearman correlation analysis of the same data set to examine correlations between rank-based changes in constipation and diarrhea, and rank-based changes in fecal metabolites. Changes in glycodeoxycholic acid-3-sulfate and caffeic acid were correlated with changes in constipation in the RPS group but not the placebo group. Levels of glycodeoxycholic acid-3-sulfate have not been previously reported in stool. Caffeic acid is a common dietary phenolic compound found in a variety of plant-derived foods

[0045] and fecal water levels tend to be 52 ± 47 pmol / L

[0046] . Caffeic acid and it’s metabolites have been extensively studied in the context of gut microbes. Gut bacteria can degrade caffeic acid to dihydrocaffeic acid and on to m-hydroxyphenylpropionic acid (also known as 3-(3-hydroxyphenyl)-propionic acid

[0047] . In RPS consuming participants experiencingType 1 or 2 stools, changes in constipation were not correlated with changes in dihydrocaffeic acid (p = 0.359, p = 0.05, q = 0.93713) or changes in 3-(3-hydroxyphenyl)-propionic acid (p = 0.004, p = 1.0, q =1.0). Caffeic acid can also be degraded to 4-vinylcatechol and then 4-ethylcatechol, but neither of these metabolites were captured in the present analysis. Others have demonstrated that caffeic acid can also be converted by colonic microbiota to 3-(4-hydroxyphenyl) propionic acid, 4- hydroxybenzoic acid, 3- or4-hydroxyphenyl acetic acid, 2-methoxy-4-methylphenol and 3-phenylpropionic acid

[0048] . However, changes in 3-(4-hydroxyphenyl) propionic acid (p = 0.095, p = 0.6, q = 1.0), 4-hydroxybenzoic acid (p = 0.084, p = 0.7, q = 1.0), 4- hydroxyphenylacetic acid (p = -0.115, p = 0.5, q = 1.0), and phenylpropionic acid (p = 0.055, p = 0.8, q = 1.0) were not correlated with changes in constipation and the other metabolites were not captured in the present analysis. While caffeic acid is extensively modified by microbiota in the gut, connections between constipation and this metabolite have not been reported.

[0065] Tetracosahexaenoic acid, also known as FA(24:6), is an omega-3 polyunsaturated fatty acid best understood as a precursor to docosahexaenoic acid

[0049] , and connections to gut bacteria or diarrhea are not known, lndole-3-carbinol is derived from glucosinolates, a category of plant secondary metabolites, that are particularly abundant in cruciferous vegetables

[0050] . In uncooked or unprocessed sources, naturally present myrosinase enzyme hydrolyzes the glucosinolates in upper gastrointestinal tract to various metabolites, including indole-3-carbinols but cooking inactivates myrosinase, meaning that glucosinolates are converted to indole-3-carbinol by microbes in the distal gut

[0050] . Importantly, indole-3-carbinol condenses to form polycyclicaromatics in acidic environments like the stomach

[0050] , so indole-3-carbinol detected in the stool likely arises due to microbial activity in the large intestine. Supplementation of indole-3-carbinol influenced the composition of the cecal microbiome in a mouse model of prostate cancer, including changes in the phyla Deferribacteres and Firmicutes (now Bacillota)

[0051] . lndole-3-carbinol is an aryl hydrocarbon receptor (AhR) ligand, and the gut microbiome of mice fed a diet lacking AhR ligands experienced increases in Erysipelotrichaceae and Bifidobacteriaceae

[0052] . Levels of both of these bacterial families decreased when mice were fed the AhR ligand-free diet supplemented with indole-3-carbinol

[0052] . In neither mouse study did the authors report changes in stool form. A study combining porcine and murine models of bile acid diarrhea disease demonstrated that indole-3-carbinol acted as an AhR ligand, repressing expression of bile acid glucuronidation gene Ugt1a4 and improving intestinal histology, although diarrhea levels in mice consuming indole-3-carbinol were not evaluated

[0053] . Administration of 2-(indol-3-ylmethyl)-3,3'-diindolylmethane, a trimeric compound derived from indole-3-carbinol, also improved intestinal histology in a dextran sodium sulfate model of colitis

[0054] .

[0066] Changes in indole-3-carbinol were positively correlated with changes in diarrhea, suggesting that excess levels of indole-3-carbinol might contribute to diarrhea in this human cohort, which is contrary to the general beneficial effects this metabolite has on intestinal health in animal models. However, indole-3-carbinol is rapidly converted to polymeric structures, including 3,3-diindolylmethane, 2-(indol-3-ylmethyl)-3,3'-diindolylmethane, 1-(3-hydroxymethyl)-indolyl-3-indolylmethane, and indolo[3,2b]carbazole, many of which are more potent than monomeric indole-3-carbinol

[0055] . Furthermore, production of indole-3-carbinol metabolites is catalyzed by microbiota in the gut

[0051]

[0052] . One possible interpretation of the findings presented here is that supplementation with RPS stimulates the conversion of indole-3-carbinol to one or more metabolites, which stimulate AhR pathways to reduce diarrhea while also reducing indole-3-carbinol levels. Unfortunately, these indole-3-carbinol metabolites were not captured in the present analysis, preventing us from testing this hypothesis. While indole-3-carbinol and related metabolites have been studied in the context of the gut microbiome, levels of indole-3-carbinol are not typically captured in indole panels due to their derivation from glucosinolates, not tryptophan

[0056] .

[0067] lndole-3-aldehyde is chemically related to indole-3-carbinol but is derived from tryptophan via microbial activity, specifically by lactobacilli

[0057] . lndole-3-aldehyde levels in the stool can alsobe potentiated by probiotic supplementation with Bifidobacterium species, like B. longum BB536

[0058] . Levels of indole-3-aldehyde are normally undetectable in stool, with a notable exception being when B. longum BB536 is administered

[0058] . Like indole-3-carbinol, indole-3-aldehyde similarly acts as an AhR ligand to influence transcription of mucosal protection from inflammation

[0057] . Levels of tryptophan (p = -0.234, p = 0.4, q = 0.5), and other related indole metabolites, including indole (p = 0.515, p = 0.06, q = 0.3), indole-3-acetic acid (p = 0.431 , p = 0.1, q = 0.3), indole-3-acrylic acid (p = 0.391, p = 0.2, q = 0.4), 5-hydroxyindole acetic acid (p = -0.122, p = 0.7, q = 0.5), and indole-3-lactic acid (p = -0.005, p = 1.0, q = 1.0) were not correlated with changes in diarrhea in RPS-consuming participants who experienced Type 7 stools, suggesting this effect is limited to a subset of indole-containing metabolites. Changes in indole-3-aldehyde have not previously been connected to changes in stool form.

[0068] Taken together, these results show that prebiotic supplementation with RPS alters the metabolic activity of the gut microbiome to reduce diarrhea- and constipation-causing metabolites and increase the abundance of metabolites with diarrhea protective effects.

[0069] Phenylethylamine, tryptamine, and tyramine, which are derived from phenylalanine, tryptophan, and tyrosine, respectively, are biogenic amines that are elevated in patients with irritable bowel syndrome type diarrhea

[0024] . Levels of phenylethylamine are higher in individuals with diarrhea (mean value 16 nM / g feces with a range of 2.0-90.0 nM / g feces) compared to healthy individuals (mean value 2.8nM / gfeces with a range of 2.1 -9.8 nM / g feces)

[0059] and relative abundance is 1.5X greater in individuals with Crohn’s disease compared to controls

[0060] .

[0070] Decreases in phenylethylamine were correlated with reductions in diarrhea in the RPS treatment group while levels of tryptamine and tyramine were not. Ruminococcus gnavus produced elevated phenylethylamine and tryptamine, which were correlated with elevated serotonin and diarrhea

[0024] . Changes in phenylethylamine were correlated with changes in diarrhea in the RPS treatment group, as were changes in serotonin, but levels of tryptamine and tyrosine were not. No bacterial taxa were correlated with changes in diarrhea

[0014] , suggesting that changes in Ruminococcus are not solely responsible for the improvements in diarrhea in the RPS treatment group. These findings are intriguing because they suggest that RPS may normally increase fecal serotonin, but that this increase may be repressed in individuals with diarrhea. Normal fecal levels of serotonin are around 5 + / -18 nmol / gin samples from healthy controls but were undetectable in irritable bowel syndrome patients with symptom exacerbation

[0061] .As will be appreciated by one of skill in the art, it is surprising that increases in Bifidobacterium are not strongly correlated with improvements in diarrhea given the healthpromoting benefits of this bacterium. However, there are so-called ‘guilds’ of bacteria that share similar metabolic capabilities and can produce similar effects

[0062] , suggesting that RPS may be enhancing a ‘diarrhea-reducing guild of bacteria’. But this is even more surprising given that there is no evidence for a broad array of bacterial genera / species being able to use RPS as an energy source. The only way RPS is known to influence the microbiome is by feeding Bifidobacterium or Ruminococcus directly and cross-feeding other bacteria

[0063] , but it is unclear if cross-feeding can selectively promote the growth of bacteria associated with diarrhea reduction.

[0071] Interestingly, serotonin levels were significantly lower in participants experiencing a reduction in diarrhea in the placebo treatment group (responders). This is consistent with what we know about serotonin and diarrhea

[0025] . RPS induced increases in serotonin, but only in the participants who did not have diarrhea to begin with (non-responders). While not wishing to be restricted or limited to a particular hypothesis, the inventor believes that RPS normally promotes serotonin increases, but this effect was blocked in people who had diarrhea (responders).

[0072] In addition to phenylethylamine, three other diarrhea-correlated metabolites were found to be reduced in responders in initial analysis of the RPS treatment group, including 3,5-DHBA, -aminobutyric acid, and thiamine. 3,5-dihydrobenzoic acid is a fermentation product of alkylresorcinols

[0064] , long-chain phenolic lipids, that are abundant in wheat, rye, and barley, which reflect gluten intake

[0065] . Levels of 3,5-DHBA increase from 0.67 pmol / g dry fecal material to 1.3 pmol / g dry fecal material after the fermentation of pseudocereals like quinoa

[0066] . Systemically, 3,5-DHBA is thought to act through the lactate receptor HCAR1 (also known as GPR81)

[0026] .

[0073] However, changes in stool lactate tended to be inversely correlated with changes in diarrhea. However, differences in lactic acid failed to differentiate diarrhea responders from non-responders in the RPS treatment group. These results suggest that 3,5-DHBA and lactic acid are not influencing stool form in parallel in RPS-consuming individuals. Although a role for 3,5-DHBA in diarrhea has not previously been reported, it is intriguing to speculate that 3,5-DHBA might playa role in nonceliac gluten sensitivity, a self-reported condition that includes diarrhea but does not have a definitive cause

[0067] .As such, in another embodiment of the invention, the individual in need of such treatment is an individual who has been diagnosed with orsuffers from orwho is suspected to sufferfrom nonceliac gluten sensitivity.

[0074] Outside of the plant kingdom, p-aminobutyric acid has not been well characterized, but levels have been detected in stool

[0068]

[0069] . In vitro studies have demonstrated ligand-like activity similar to y-aminobutyric acid. Stimulation of the intestinal cell line Caco-2 cells with p-aminobutyric acid led to cellular acidification, increased short circuit current, and reduced uptake of y-aminobutyric acid and beta-alanine

[0028] . Using an overexpression Xenopus oocyte model, p-aminobutyric acid was found to have concentration-dependent effects on the human alpha 1 glycine receptor with low concentrations competitively inhibiting a glycine response and higher concentrations inducing significant membrane currents

[0027] . Furthermore, taurine transport can be inhibited by p-aminobutyric acid in invertebrates

[0070] . Among these related metabolites and signaling systems, only changes in taurine tended to be correlated with changes in diarrhea, with increases in taurine tending to differentiate diarrhea responders from non-responders in the RPS treatment group. Further work is required to understand how reductions in p-aminobutyric acid and / or increases in taurine may promote a reduction in diarrhea.

[0075] Resistant potato starch-dependent improvements in diarrhea were also correlated with increases in presumably beneficial metabolites, including the dimeric amino acid cystine. Fecal relative abundance of both cystine and the monomeric amino acid cysteine are approximately twice as high in patients with chronic kidney disease as they are in the control population

[0071] . Cystine is known to reduce intestinal fluid secretion associated with pathogenic bacterial infection, as well as reducing pathogenic toxin production

[0072]

[0073] . Supplementation of cystine, either alone or in combination with theanine, enhances intestinal barrier function and reduces diarrhea in animal models and patients receiving chemotherapy

[0074]

[0075]

[0076]

[0077] . Changes in the amino acid cysteine were also correlated with changes in diarrhea. Given that these metabolites influence the oxidative-reductive status of a system

[0077] , it was possible that increases in cystine and cysteine levels improved diarrhea via reduced oxidative stress. However, levels of metabolites associated with cysteine metabolism and counteracting oxidative stress were not correlated with changes in diarrhea, suggesting other mechanisms must be at work.

[0076] Levels of acetyl putrescine increase (from 100 ng / 0.05 mL of supernatant in donors to 430 ng / 0.05 mL of supernatant post fecal microbiome transplant) along with spermidine, acetate, andbutyrate after fecal microbiome transplant in patients with recurrent Clostridium difficile infection

[0078] , demonstrating that N1 -acetyl spermidine plays a role in certain forms of diarrhea. However, changes in N1 -acetyl spermidine did not significantly differentiate diarrhea responders from nonresponders in the RPS treatment group, suggesting this metabolite does not playa central role. The remaining diarrhea-correlated metabolites in the RPS treatment group tended to increase with high variability during week 4 in diarrhea responders. Four of these metabolites were acylcarnitines, which are normally involved in host fatty acid metabolism but can also be used by various bacteria as sources of carbon, nitrogen, and energy

[0079] . Longer (>6C) fecal acylcarnitines have been associated with beneficial diets

[0080] as well as diseased states

[0081]

[0082]

[0083]

[0084] , but specific gut or bacterial roles for the acylcarnitines identified here have not been reported. Normallevels of total acylcarnitines in feces range between 14.12-16.69 nmol / g feces, with levels of hydroxyhexadecanoylcarnitine ranging between 0.20-0.36 nmol / g feces and propionylcarnitine ranging between 0.15-0.27 nmol / g feces

[0080] . Orotic acid excretion is proportional to nitrogen intake

[0085] , but connections to diarrhea are not known. Phenyllactic acid is a normal constituent of the fecal metabolome and is produced by beneficial bacteria in the infant gut

[0086]

[0087] , but connections to diarrhea have not previously been made. Normal average levels of pheyllactic acid range from 20.4-54.9 nmol / g feces

[0087] . While both lactose and maltose are disaccharides, only lactose is typically associated with causing diarrhea

[0088] . How increases in lactose or maltose might decrease diarrhea remains to be elucidated.

[0077] Upon reanalysis of the data set using the last 6 days of the week 1 time point, twelve additional metabolites were found to be inversely correlated with changes in diarrhea in the RPS treatment group. 1-methyl-4-imidazoleacetic acid is a major metabolite of histamine metabolism

[0089] . RPS is known to reduce serum histamine levels, but analysis of serum metabolites of histamine degradation did not support a direct role for RPS in histamine metabolism, suggesting that histamine reductions were due to improvements in intestinal barrier function

[0019] . Notably, changes in fecal histamine were not correlated with either constipation (r = 0.050; p = 0.7) or diarrhea (r = 0.048; p = 0.7), suggesting that upstream changes in histamine abundance are not driving the correlations between changes in stool form and these metabolites.

[0078] Imidazolepropionic acid is produced by bacterial urocanate reductase from urocanate, a histidine breakdown product

[0090] . Serum levels are elevated in individuals with type 2 diabetes, where it acts via the mTORCI pathway to promote insulin receptor substrate phosphorylation andinsulin insensitivity

[0091] . Levels of imidazolepropionic acid were not detected in serum samples in the present study, suggesting that the reported effects of RPS on free fatty acid levels are independent of changes in imidazolepropionic acid

[0092] , and that the effects of this metabolite on constipation and diarrhea are due to local activities. The concentration of urocanate in the stool of placebo- and RPS-consuming participants was sufficient to promote substantial urocanate reductase activity in vitro

[0093] . However, urocanate levels were not correlated with changes in either constipation (r = 0.109; p = 0.5) or diarrhea (r = 0.166; p = 0.3) in RPS-consuming participants, suggesting that RPS-dependent correlations between imidazolepropionic acid and changes in stool form are likely due to changes in microbial activity rather than urocanate abundance. Similarly, while levels of imidazolepropionic acid have been correlated with changes in bacterial abundance

[0090] , none of these bacterial groups were significantly correlated with changes in stool form in RPS-consuming individuals, where changes in Granulicatella, Turicibacter, and unclassified Gammaproteobacteria were correlated with changes in constipation

[0014] . These findings further support the conclusion that RPS-mediated improvements in stool form that are correlated with changes in imidazolepropionic acid are due to changes in urocanate reductase activity.

[0079] Linoleyl carnitine , palmitoylcarnitine, myristoylcarnitine, oleoylcarnitine, and isobutyrylcarnitine were additional diarrhea-correlated acylcarnitines identified in the reanalysis. However, like the previously identified acylcarnitines, no previous connections between these metabolites and changes in stool form have been reported. While sulfation of bile acids is known to enhance their excretion, largely through urine

[0094] , hyodeoxycholic acid-3-sulfate has not been previously linked to changes in stool form. Similarly, fecal levels of 3-hydroxyaspartic acid have not been reported, and no connection between changes in this metabolite and changes in stool form have been reported.

[0080] Administration of bile acids like ursodeoxycholic acid and chenodeoxycholic acid in cholestatic and non-cholestatic liver disease is known to cause diarrhea as a side effect

[0095]

[0096] , but increases in the fecal abundance of these bile acids have not previously been associated with improvements in diarrhea. Average fecal levels of ursodeoxycholic acid range from 11.1-18.8 ng / mL and average fecal levels of chenodeoxycholic acid range from 5.5-14.3 ng / mL

[0097] . While phosphocholine is found in the majority of fecal samples tested, neither normal nor abnormal levels have been reported

[0098] .While a constipation-associated role for hydroxypalmitic acid has not been reported, a species of Shigella isolated from individuals with intractable functional constipation was shown to synthesize docosapentanoic acid and induce constipation in mice

[0099] . Notably, docosa pentanoic acid was found to inhibit colonic contraction force by 20% at a concentration of 3 pM

[0099] , while reductions averaged 20-30 nM in constipation responders consuming RPS. While phage treatment targeting docosapentanoic acid-producing Shigella was effective at reducing constipation in infected mice

[0099] , changes in Shigella were not correlated with changes in constipation in RPS consuming individuals (r = -0.022; p = 0.9), further suggesting that RPS influences bacterial activity rather than relative abundance to improve stool form. While changes in dietary docosapentanoic acid could feasibly cause the changes observed in the RPS treatment group, macronutrient intake did not change during the study

[0014] and dietary docosa pentanoic acid did not influence constipation

[0099] , supporting the conclusion that changes in bacterial activity are responsible for the changes in stool form reported in the RPS treatment group.

[0081] Excessive bile acids are normally associated with diarrhea

[0034] , rather than constipation, and sulfated bile acids are known to be poorly absorbed despite being more water soluble

[0036] , which is consistent with the correlations between reductions in sulfated bile acids and reductions in constipation in the RPS treatment group. Normal levels of lithocholic acid-3-sulfate are 0.77 + / -0.63 nmol / g dry feces

[0100] and deoxycholic acid-3-sulfate are 9.36 + / - 15.51 nmol / g dry feces

[0100] , while normal fecal levels of cholic acid-7-sulfate and hyodeoxycholic acid-3-sulfate are not known.

[0082] Analysis of correlations between changes in bacterial taxa and changes in constipation in the same population described here identified that reductions in Granulicatella, Turicibacter, and unclassified Gammaproteobacteria were associated with improvements in constipation in RPS consuming participants

[0014] . Notably, that same study did not detect any significant correlations between changes in bacterial taxa and changes in diarrhea

[0014] . The discoveries reported here elaborate on previous findings, demonstrating that RPS supplementation modulates the activity of the gut microbiome to promote improvements in individuals experiencing constipation and diarrhea. This mechanism of action involves both reducing diarrhea-causing metabolites like phenylethylamine and increasing diarrhea-protective metabolites like cystine while the mechanism of action underlying constipation improvements involves reductions in constipation-causing metabolites like FA(22:5). Perhaps most remarkable is that RPS tends to decrease the abundanceof imidazolepropionic acid, 1-methyl-4-imidazoleacetic acid, and hyodeoxycholic acid-3-sulfate in constipation responders while increasing these same metabolites in diarrhea responders.

[0083] According to an aspect of the invention, there is provided a method of modifying levels of a microbially-influenced metabolite in the large intestine generated by resistant potato starch fermentation in the human’s gut comprising administering to said human an effective amount of a suitable resistant potato starch on a dosage regimen.

[0084] In some embodiments, the microbially-influenced metabolite is a biogenic amine, amino acid, dibasic amino acid, polyamine, carnitine, purine metabolite, dibasic sugar, vitamin, neurotransmitter, or alkyresorcinol fermentation product, or a fatty acid, imidazole acid, bile acid, sulfated bile acid, hydroxyamino acid, or phosphorylated choline.

[0085] In some embodiments, the microbially-influenced metabolite is selected from the group consisting of phenylethylamine, 3,5-dihydroxybenzoic acid, cystine, N1-acetyl putrescine, betaaminobutyric acid, thiamine, 3-hydroxyhexadecanoylcarnitine, 3-methylcrotonyl-L-carnitine, orotic acid, propionylcarnitine, maltose, lactose, 2-methylbutyrylcarnitine, phenyllactic acid, serotonin, or cysteine, or 1-methyl-4-imidazoleacetic acid, imidazolepropionic acid, linoleyl carnitine , hyodeoxycholic acid-3-sulfate, 3-hydroxyaspartic acid, palmitoylcarnitine, myristoylcarnitine, oleoylcarnitine, ursodeoxycholic acid, chenodeoxycholic acid, phosphocholine, isobutyrylcarnitine, FA(16:0-OH), lithocholic acid-3-sulfate, deoxycholic acid-3-sulfate, cholic acid-7-sulfate, or FA(22:5).

[0086] According to an aspect of the invention, there is provided a method of decreasing fecal phenylethylamine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0087] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal phenylethylamine levels are higher than a control individual, for example, higher than 2.8nM / g in feces or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, related diarrhea, for example, is supplementing with phenylethylamine or deliberately consuming foods rich in phenylalanine, or otherwise is in need of reduced intestinal protein fermentation. As discussed herein, for example, RPS-consuming participants who had diarrhea-associated (type 7) BMs experienced these as 9.5% of all BMs during the baseline / run-in period (before treatment). As such, an individual in need of such treatment would be an individual suffering from diarrhea-associated (type 7) BMs approximately at least 5-10% of the time over a given period of time, for example, about at least once or about at least twice in a two week period.

[0088] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal phenylethylamine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0089] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for treating frequent diarrhea, for example, irritable bowel syndrome-related diarrhea or incontinence.

[0090] According to another aspect of the invention, there is provided use of native RPS (RS type 2) fortreatinga disorderforwhich diarrhea is a primary symptom or complaint, forexample, irritable bowel syndrome, inflammatory bowel disease, or some other intestinal condition.

[0091] According to another aspect of the invention, wherein the individual is supplementing their diet with phenylethylamine or foods rich in phenylalanine there is provided use of native RPS (RS type 2) for diarrhea reduction.

[0092] According to an aspect of the invention, there is provided a method of decreasing fecal 3,5-dihydrobenzoic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0093] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 3,5-dihydrobenzoic acid levels are higher than a control individual, higher than 0.67 pmol / g dry fecal material, forexample, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea, or individuals with non-celiac gluten sensitivity, or individuals sensitive to fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs).

[0094] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal 3,5-dihydrobenzoic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0095] According to another aspect of the invention, wherein the individual is consuming foods containing wheat, barley, rye, quinoa, or foods rich in alkylresorcinols, there is provided use of native RPS (RS type 2) for diarrhea reduction.According to an aspect of the invention, there is provided a method of decreasing fecal beta-aminobutyric acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0096] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal beta-aminobutyric acid levels are higher than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0097] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal beta-aminobutyric acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0098] According to an aspect of the invention, there is provided a method of decreasing fecal thiamine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0099] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal thiamine levels are higher than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0100] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal thiamine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0101] According to another aspect of the invention, wherein the individual is supplementing their diet with thiamine or foods rich in thiamine there is provided use of native RPS (RS type 2) for diarrhea reduction.

[0102] According to an aspect of the invention, there is provided a method of preventing the increase in fecal serotonin levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0103] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal serotonin levels are higher than a control individual, whose fecal serotonin levels are higher than 5 + / -18 nmol / g, for example, or an individual who suffers from frequent diarrhea, forexample, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0104] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for preventing an increase in fecal serotonin levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0105] According to another aspect of the invention, wherein the individual is supplementing their diet with serotonin or foods rich in tryptophan there is provided use of native RPS (RS type 2) for diarrhea reduction.

[0106] According to an aspect of the invention, there is provided a method of increasing fecal cystine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0107] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal cystine levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0108] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal cystine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0109] According to an aspect of the invention, there is provided a method of increasing fecal N1-acetyl putrescine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0110] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal N1-acetyl putrescine levels are lowerthan a control individual, lowerthan 100 ng / 0.05 mL of fecal supernatant, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0111] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal N1-acetyl putrescine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").According to an aspect of the invention, there is provided a method of increasing fecal 3-hydroxyhexadecanoylcarnitine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0112] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 3-hydroxyhexadecanoylcarnitine levels are lower than a control individual, with total acylcarnitine levels lower than 14.0 nmol / g feces, for example, with levels of hydroxyhexadecanoylcarnitine lower than 0.2 nmol / g, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0113] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal 3-hydroxyhexadecanoylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0114] According to an aspect of the invention, there is provided a method of increasing fecal 3-methylcrotonyl-L-carnitine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0115] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 3-methylcrotonyl-L-carnitine levels are lower than a control individual, with total acylcarnitine levels lower than 14.0 nmol / g feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0116] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal 3-methylcrotonyl-L-carnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0117] According to an aspect of the invention, there is provided a method of increasing fecal orotic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0118] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal orotic acid levels are lower than a control individual, or an individual who suffers fromfrequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0119] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal orotic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0120] According to an aspect of the invention, there is provided a method of increasing fecal propionylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0121] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal propionylcarnitine levels are lower than a control individual, with total acylcarnitine levels lowerthan 14.0 nmol / gfeces, forexample, with propionylcarnitine levels lowerthan 0.15 nmol / g feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0122] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal propionylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0123] According to an aspect of the invention, there is provided a method of increasing fecal maltose levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0124] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal maltose levels are lowerthan a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0125] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal maltose levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").According to an aspect of the invention, there is provided a method of increasing fecal lactose levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0126] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal lactose levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0127] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal lactose levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0128] According to another aspect of the invention, wherein the individual is lactose intolerant or has a milk allergy there is provided use of native RPS (RS type 2) for diarrhea reduction.

[0129] According to an aspect of the invention, there is provided a method of increasing fecal 2-methylbutyrylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0130] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 2-methylbutyrylcarnitine levels are lower than a control individual, with total acylcarnitine levels lower than 14.0 nmol / g feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0131] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal 2-methylbutyrylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0132] According to an aspect of the invention, there is provided a method of increasing fecal phenyllactic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0133] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal phenyllactic acid levels are lower than a control individual, whose fecal phenyllactic acid levels are lower than 20.4 nmol / g feces, for example, or an individual who suffers fromfrequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0134] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal phenyllactic acid levels orfor reducingthe severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0135] According to an aspect of the invention, there is provided a method of increasing fecal lactic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0136] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal lactic acid levels are lower than a control individual, whose fecal lactic acid levels are lower than 5 pmol / g feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0137] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal lactic acid levels orfor reducingthe severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0138] According to an aspect of the invention, there is provided a method of increasing fecal cysteine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0139] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal cysteine levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0140] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal cysteine levels orfor reducingthe severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0141] According to an aspect of the invention, there is provided a method of increasing fecal taurine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.As such, in this context, “an individual in need of such treatment” may be an individual whose fecal taurine levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0142] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal taurine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0143] According to an aspect of the invention, there is provided a method of increasing fecal 1-methyl-4-imidazoleacetic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0144] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 1-methyl-4-i midazoleacetic acid levels are lower than a control individual, whose urine 1-methyl-4-imidazoleacetic acid levels are lower than 1.25 umol / mmol creatinine, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0145] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal 1-methyl-4-imidazoleacetic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0146] According to an aspect of the invention, there is provided a method of increasing fecal imidazolepropionic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0147] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal imidazolepropionic acid levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0148] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal imidazolepropionic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").According to an aspect of the invention, there is provided a method of increasing fecal linoleyl carnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0149] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal linoleyl carnitine levels are lower than a control individual, whose fecal linoleyl carnitine levels are lower than 0.1 nmol / g wet feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0150] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal linoleyl carnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0151] According to an aspect of the invention, there is provided a method of increasing fecal hyodeoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0152] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal hyodeoxycholic acid-3-sulfate levels are lower than 9.36 nmol / g dry feces, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0153] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal hyodeoxycholic acid-3-sulfate levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0154] According to an aspect of the invention, there is provided a method of increasing fecal 3-hydroxyaspartic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0155] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 3- hydroxyaspartic acid levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal 3-hydroxyaspartic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0156] According to an aspect of the invention, there is provided a method of increasing fecal palmitoylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0157] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal palmitoylcarnitine levels are lower than a control individual, whose fecal palmitoylcarnitine levels are lower than 0.22 nmol / g wet feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0158] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal palmitoylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0159] According to an aspect of the invention, there is provided a method of increasing fecal myristoylcarnitine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0160] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal myristoylcarnitine levels are lower than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0161] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal myristoylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0162] According to an aspect of the invention, there is provided a method of increasing fecal oleoylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0163] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal oleoylcarnitine levels are lower than a control individual, or an individual who suffersfrom frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0164] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal oleoylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0165] According to an aspect of the invention, there is provided a method of increasing fecal ursodeoxycholic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0166] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal ursodeoxycholic acid levels are lower than a control individual, whose fecal ursodeoxycholic acid levels are lower than 27.05 nmol / g dry feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0167] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal ursodeoxycholic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0168] According to an aspect of the invention, there is provided a method of increasing fecal chenodeoxycholic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0169] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal chenodeoxycholic acid levels are lower than a control individual, whose fecal chenodeoxycholic acid levels are lower than 54.8 nmol / g dry feces, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0170] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal chenodeoxycholic acid levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").According to an aspect of the invention, there is provided a method of increasing fecal phosphocholine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0171] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal phosphocholine levels are lower than a control individual, whose urine phosphocholine levels are lower than 1.1 pmol / mmol creatinine, for example, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0172] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal phosphocholine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0173] According to an aspect of the invention, there is provided a method of increasing fecal isobutyrylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0174] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal isobutyrylcarnitine levels are lower than a control individual, whose urine isobutyrylcarnitine levels are lowerthan 0.05 pmol / mmol creatinine, for example, oran individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0175] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for increasing fecal isobutyrylcarnitine levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0176] According to an aspect of the invention, there is provided a method of decreasing fecal FA(16:0-OH) levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0177] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal FA(16:0-OH) levels are higher than a control individual, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal FA(16:0-OH) levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0178] According to an aspect of the invention, there is provided a method of decreasing fecal lithocholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0179] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal lithocholic acid-3-sulfate levels are higher than 0.77 nmol / g dry feces, for example, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0180] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal lithocholic acid-3-sulfate levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0181] According to an aspect of the invention, there is provided a method of decreasing fecal deoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0182] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal deoxycholic acid-3-sulfate levels are higher than a control individual, whose fecal deoxycholic acid-3-sulfate levels are higher than 9.36 nmol / g dry feces, for example, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0183] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal deoxycholic acid-3-sulfate levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0184] According to an aspect of the invention, there is provided a method of decreasing fecal imidazolepropionic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.As such, in this context, “an individual in need of such treatment” may be an individual whose fecal imidazolepropionic acid levels are higher than a control individual, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0185] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal imidazolepropionic acid levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0186] According to an aspect of the invention, there is provided a method of decreasing fecal 1-methyl-4-imidazoleacetic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0187] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal 1-methyl-4-imidazoleacetic acid levels are higher than a control individual, whose urine 1-methyl-4-imidazoleacetic acid levels are higher than 1.25 umol / mmol creatinine, for example, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0188] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal 1-methyl-4-imidazoleacetic acid levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0189] According to an aspect of the invention, there is provided a method of decreasing fecal hyodeoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0190] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal hyodeoxycholic acid-3-sulfate levels are higher than a control individual, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0191] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal hyodeoxycholic acid-3-sulfate levels or for reducing the severity and / orfrequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0192] According to an aspect of the invention, there is provided a method of decreasing fecal cholic acid-7-sulfate levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0193] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal cholic acid-7-sulfate levels are higher than a control individual, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0194] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal cholic acid-7-sulfate levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0195] According to an aspect of the invention, there is provided a method of decreasing fecal FA(22:5) levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0196] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal FA(22:5) levels are higher than a control individual, whose urine FA(22:5) levels are higher than 6.4 pmol / mmol creatinine, for example, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0197] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal FA(22:5) levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0198] According to another aspect of the invention, wherein the individual has elevated levels of FA(22:5)-producing Shigella bacteria in the gut, there is provided use of native RPS (RS type 2) for constipation reduction.

[0199] According to an aspect of the invention, there is provided a method of decreasing fecal linoleyl carnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.As such, in this context, “an individual in need of such treatment” may be an individual whose fecal linoleyl carnitine levels are higher than a control individual, whose fecal linoleyl carnitine levels are higher than 0.36 nmol / g wet feces, for example, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0200] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing fecal linoleyl carnitine levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0201] According to an aspect of the invention, there is provided a method of decreasing fecal glycodeoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0202] As such, in this context, “an individual in need of such treatment” may be an individual who’s fecal glycodeoxycholic acid-3-sulfate levels are higher than a control individual, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0203] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing glycodeoxycholic acid-3-sulfate levels or for reducing the severity and / or frequency of constipation compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0204] According to an aspect of the invention, there is provided a method of decreasing fecal caffeic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0205] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal caffeic acid levels are higher than a control individual, whose baseline caffeic acid levels in fecal water above 52 ± 47 pmol / L, for example, or an individual who suffers from frequent constipation, for example, irritable bowel syndrome associated constipation or intractable functional constipation, or related constipation.

[0206] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing caffeic acid levels or for reducing the severity and / or frequency of constipationcompared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0207] According to an aspect of the invention, there is provided a method of decreasing fecal FA(24:6) levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0208] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal FA(24:6) levels are higher than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0209] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing FA(24:6) levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0210] According to an aspect of the invention, there is provided a method of decreasing fecal indole-3-carbinol levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0211] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal indole-3-carbinol levels are higher than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.

[0212] According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing indole-3-carbinol levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0213] According to an aspect of the invention, there is provided a method of decreasing fecal indole-3-aldehyde levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

[0214] As such, in this context, “an individual in need of such treatment” may be an individual whose fecal indole-3- aldehyde levels are higher than a control individual, or an individual who suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease, or related diarrhea.According to another aspect of the invention, there is provided use of native RPS (RS type 2) for decreasing indole-3- aldehyde levels or for reducing the severity and / or frequency of diarrhea compared to an individual of similar age and condition not administered the dosage regimen (referred to herein elsewhere as a "control individual").

[0215] In some embodiments of the invention, the resistant potato starch is administered daily for a period of 1-12 weeks. In this context, “daily” does not necessarily mean “every day” but may mean for example 19 out of 20 days, 9 out of 10 days, 17 out of 20 days or 8 out of 10 days.

[0216] As discussed herein, the effective amount may be, for example, 0.5 to 40g, or 0.5 to 30g, or 0.5 to 7g, or 0.5 to 3.5g of resistant starch.

[0217] While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.Table 1. Correlations between changes in stool metabolites and changes in constipation in participants consuming 3.5g RPS.

[0218] Diarrhea Correlation Constipation Correlation Metabolite

[0219] Pearson R2p Value q Value Pearson R2p Value q Value Phenylethylamine 0.598 0.358 0.000007 0.0003 0.018 0.0003 0.9 0.0881 3,5-Dihydroxybenzoic Acid 0.535 0.286 0.00009 0.0005 -0.242 0.058 0.1 0.0106 Cystine -0.494 0.244 0.0004 0.0008 0.224 0.050 0.1 0.0143 N1 -Acetyl Putrescine -0.486 0.236 0.0005 0.0011 0.3334 0.111 0.02 0.0056 |3-Aminobutyric Acid 0.481 0.232 0.0005 0.0013 0.134 0.018 0.4 0.0333 Thiamine 0.476 0.226 0.0006 0.0016 0.021 0.0004 0.9 0.0857 -Hydroxyhexadecanoylcarnitine -0.461 0.213 0.001 0.0019 0.076 0.006 0.6 0.0542 3-Methylcrotonyl-L-Carnitine -0.451 0.203 0.001 0.0021 -0.020 0.0004 0.9 0.0862 Orotic Acid -0.444 0.197 0.002 0.0024 0.035 0.001 0.8 0.0780 Propionylcarnitine -0.443 0.196 0.002 0.0026 0.076 0.006 0.6 0.0540 Maltose -0.442 0.195 0.002 0.0029 0.058 0.003 0.7 0.0659 Lactose -0.441 0.194 0.002 0.0032 0.058 0.003 0.7 0.0661 2-Methylbutyrylcarnitine -0.433 0.187 0.002 0.0034 0.022 0.0005 0.9 0.0841

[0220]

[0221] Phenyllactic Acid -0.420 0.176 0.003 0.0037 0.044 0.002 0.8 0.0733

[0222] Table 2. Correlation analysis of changes in alkylresorcinol-related metabolites and changes in diarrhea.

[0223] Metabolite Pearson R2p Value Lactate -0.286 0.082 0.05 Protocatechuic Acid -0.045 0.002 0.8

[0224]

[0225] 4- Hyd roxy b e n zo i c Ac i d -0.089 0.008 0.5

[0226] Table 3. Correlation analysis of changes in cysteine metabolism metabolites and changes in diarrhea.

[0227] Metabolite Pearson R2p Value Cysteine -0.349 0.122 0.01 Methionine 0.097 0.009 0.5

[0228] S-Adenosylmethionine ND - - S-Adenosylhomocysteine -0.130 0.017 0.4 Homocysteine 0.044 0.002 0.8 Cystathionine -0.081 0.006 0.6 Cysteinesulfinic Acid -0.023 0.001 0.9 Glutamylcysteine -0.017 0.000 0.9 Arginine 0.166 0.028 0.3

[0229]

[0230] Glutathione Disulfide -0.067 0.004 0.7Table 4. Correlation analysis of changes in glycine receptor agonists and changes in diarrhea. Metabolite Pearson R2p Value Glycine -0.072 0.005 0.6

[0231] Alanine 0.024 0.001 0.9

[0232] B-Alanine -0.068 0.005 0.6

[0233] y-Aminobutyric -0.126 0.016 0.4 Hypotaurine -0.038 0.001 0.8

[0234] Proline 0.192 0.037 0.2

[0235] Sarcosine 0.082 0.007 0.6

[0236] Serine 0.023 0.001 0.9

[0237]

[0238] Taurine -0.305 0.093 0.04

[0239] Table 5. Correlation analysis of changes in y-aminobutyric acid, position isomers, and related non- proteinogenic amino acids and changes in diarrhea.

[0240] Metabolite Pearson R2p Value

[0241] a-Aminobutyric Acid -0.075 0.006 0.6

[0242] y-Aminobutyric Acid -0.126 0.016 0.4

[0243] 5-Aminovalerlic Acid -0.048 0.002 0.7

[0244]

[0245] Aminocaproic Acid 0.099 0.010 0.5

[0246] Table 6. Correlation analysis of changes in constipation and changes in metabolites in the revised 6 day duration of the week 1 time point.

[0247] Constipation Correlation Diarrhea Correlation Metabolite

[0248] Pearson R2p Value q Value Pearson R2p Value q Value FA(16:0-OH) 0.495 0.245 0.0003 0.0003 -0.256 0.066 0.08 0.02 Lithocholic Acid-3-Sulfate 0.485 0.235 0.0005 0.0005 -0.360 0.130 0.01 0.01 Deoxycholic Acid-3-Sulfate 0.485 0.235 0.0005 0.0008 -0.369 0.136 0.01 0.009 Imidazole Propionic Acid 0.476 0.226 0.0006 0.001 -0.459 0.211 0.001 0.002 1-Methyl-4-lmidazoleacetic Acid 0.475 0.225 0.0007 0.001 -0.463 0.214 0.0009 0.001 Hyodeoxycholic Acid-3-Sulfate 0.466 0.217 0.0009 0.002 -0.441 0.195 0.002 0.003 Cholic Acid-7-Sulfate 0.458 0.209 0.001 0.002 -0.375 0.141 0.009 0.008 FA(22:5) 0.448 0.201 0.001 0.002 -0.071 0.005 0.6 0.06

[0249]

[0250] Linoleyl carnitine 0.433 0.188 0.002 0.002 -0.451 0.204 0.001 0.002Table 7. Correlation analysis of changes in diarrhea and changes in metabolites in the revised 6 day duration of the week 1 time point.

[0251] Diarrhea Correlation Constipation Correlation Metabolite

[0252] Pearson R2p Value q Value Pearson R2p Value q Value Phenylethylamine 0.561 0.315 0.00003 0.0003 0.016 0.000 0.9 0.09 N1 -Acetyl Putrescine -0.538 0.289 0.00008 0.0005 0.384 0.148 0.007 0.004 3,5-Dihydroxybenzoic Acid 0.517 0.267 0.0002 0.0008 -0.241 0.058 0.1 0.01 Cystine -0.494 0.244 0.0004 0.001 0.244 0.060 0.1 0.01 1-Methyl-4-lmidazoleacetic Acid -0.463 0.214 0.0009 0.001 0.475 0.225 0.0007 0.001 Imidazole Propionic Acid -0.459 0.211 0.001 0.002 0.476 0.226 0.0006 0.001 -Hydroxyhexadecanoylcarnitine -0.452 0.205 0.001 0.002 0.081 0.007 0.6 0.05 Linoleyl carnitine -0.451 0.204 0.001 0.002 0.433 0.188 0.002 0.002 Hyodeoxycholic Acid-3-Sulfate -0.441 0.195 0.002 0.003 0.466 0.217 0.0009 0.002 3- Hydroxyaspartic Acid -0.436 0.190 0.002 0.003 0.411 0.169 0.004 0.003 Palmitoylcarnitine -0.431 0.186 0.002 0.003 0.402 0.162 0.005 0.004 Myristoylcarnitine -0.430 0.185 0.002 0.003 0.300 0.087 0.04 0.009 Maltose -0.427 0.183 0.002 0.003 0.065 0.004 0.7 0.06 Lactose -0.426 0.182 0.003 0.004 0.065 0.004 0.7 0.06 Orotic Acid -0.422 0.178 0.003 0.004 0.040 0.002 0.8 0.08 Thiamine 0.422 0.178 0.003 0.004 0.018 0.000 0.9 0.09 Propionylcarnitine -0.418 0.175 0.003 0.004 0.079 0.006 0.6 0.06 3-Methylcrotonyl-L-Carnitine -0.414 0.171 0.003 0.005 -0.022 0.000 0.9 0.09 2-Methylbutyrylcarnitine -0.411 0.169 0.004 0.005 0.027 0.001 0.9 0.08 Oleoylcarnitine -0.405 0.164 0.004 0.005 0.362 0.131 0.01 0.006 Phenyllactic Acid -0.401 0.161 0.005 0.006 0.048 0.002 0.7 0.07 Ursodeoxycholic Acid -0.395 0.156 0.005 0.006 0.303 0.092 0.04 0.008 Chenodeoxycholic Acid -0.391 0.153 0.006 0.006 0.378 0.143 0.008 0.005 Phosphocholine -0.391 0.153 0.006 0.006 0.211 0.045 0.2 0.02 |3-Aminobutyric Acid 0.388 0.151 0.006 0.007 0.154 0.024 0.3 0.03

[0253]

[0254] Isobutyrylcarnitine -0.386 0.149 0.007 0.007 0.004 0.000 1.0 0.1

[0255] Table 8. Correlation analysis of changes diarrhea and changes in amino acids related to aspartate- to-threonine synthesis and glutamatergic neuron function.

[0256] Metabolite Pearson R2p Value Aspartate -0.170 0.029 0.2 Homoserine -0.190 0.036 0.2

[0257] Lysine -0.020 0.000 0.9 Methionine 0.050 0.002 0.7

[0258] Threonine -0.200 0.040 0.2

[0259] Isoleucine 0.015 0.000 0.9

[0260]

[0261] Glutamate 0.070 0.005 0.6Table 9. Correlations between changes in unconjugated fecal bile acids and changes in constipation and changes in fecal bile acids and changes in diarrhea in participants consuming 3.5g RPS.

[0262] Constipation Correlation Diarrhea Correlation Class

[0263] Bile Acid

[0264]

[0101] Pearson R2P q Pearson R P q Value Va2

[0265] lue Value Value Cholic Acid 1° 0.051 0.003 0.7 0.07 -0.367 0.136 0.01 0.009 Chenodeoxycholic Acid 1° 0.132 0.017 0.4 0.04 -0.391 0.153 0.006 0.006 Hyocholic Acid 1° 0.155 0.024 0.3 0.03 -0.327 0.107 0.02 0.01 a-Muricholic Acid 1° 0.142 0.020 0.3 0.03 -0.207 0.043 0.2 0.03 |3-Muricholic Acid 1° 0.220 0.048 0.1 0.02 -0.342 0.117 0.02 0.01 Deoxycholic Acid 0.062 0.004 0.7 0.06 -0.243 0.059 0.1 0.02 2°

[0266] Lithocholic Acid 0.027 0.001 0.9 0.08 -0.045 0.002 0.8 0.08 2°

[0267] Ursocholic Acid 0.223 0.050 0.1 0.02 -0.248 0.062 0.09 0.02 2°

[0268] Ursodeoxycholic Acid 2° 0.125 0.016 0.4 0.04 -0.395 0.156 0.005 0.006 Hyodeoxycholic Acid 2° 0.021 0.000 0.9 0.09 -0.322 0.104 0.03 0.01 w-Muricholic Acid 2° 0.054 0.003 0.7 0.07 -0.346 0.120 0.02 0.01 Allocholic Acid Derivative 0.156 0.024 0.3 0.03 -0.250 0.062 0.09 0.02 Alloisolithocholic Acid Derivative 0.024 0.001 0.9 0.09 0.009 0.000 1.0 0.1 Apocholic Acid Derivative 0.175 0.031 0.2 0.03 -0.298 0.089 0.04 0.02 Isodeoxycholic Acid Derivative -0.151 0.023 0.3 0.03 -0.344 0.119 0.02 0.01 Isolithocholic Acid Derivative -0.146 0.021 0.3 0.03 0.069 0.005 0.6 0.07 Murideoxycholic Acid Derivative 0.088 0.008 0.6 0.05 -0.131 0.017 0.4 0.05 3-Oxocholic Acid Derivative -0.044 0.002 0.8 0.08 -0.176 0.031 0.2 0.03 Dioxolithocholic Acid Derivative -0.180 0.032 0.2 0.02 -0.035 0.001 0.8 0.08 Dehydrolithocholic Acid Derivative -0.252 0.063 0.08 0.01 0.093 0.009 0.5 0.06 12-Ketochenodeoxycholic

[0269] Derivative -0.042 0.002 0.8 0.08 -0.194 0.037 0.2 0.03 Acid

[0270] 6,7-Diketolithocholic Acid Derivative -0.035 0.001 0.8 0.08 0.111 0.012 0.5 0.05 7-Ketolithocholic Acid Derivative -0.182 0.033 0.2 0.02 0.195 0.038 0.2 0.03 12-Ketolithocholic Acid Derivative -0.167 0.028 0.3 0.03 -0.043 0.002 0.8 0.08 Norcholic Acid Derivative 0.000 0.000 1.0 0.1 -0.169 0.029 0.2 0.04 Nordeoxycholic Acid Derivative -0.293 0.057 0.1 0.01 -0.011 0.000 0.9 0.1 Norursodeoxycholic Acid Derivative -0.030 0.001 0.8 0.08 0.204 0.042 0.2 0.03

[0271]

[0272] Table 10. Correlations between changes in conjugated fecal bile acids and changes in constipation and changes in fecal bile acids and changes in diarrhea in participants consuming 3.5g RPS.

[0273] Constipation Correlation Diarrhea Correlation

[0274] Bile Acid

[0275] Pearson R2p Value q Value Pearson R2p Value q Value Glycocholic Acid 0.040 0.002 0.8 0.08 -0.008 0.000 1.0 0.1 Glycochenodeoxycholic Acid 0.014 0.000 0.9 0.09 -0.032 0.001 0.8 0.08 Glycohyocholic Acid -0.016 0.000 0.9 0.09 0.022 0.000 0.9 0.09 Glyco-a-Muricholic Acid -0.028 0.001 0.9 0.08 0.022 0.000 0.9 0.09 Glyco-|3-Muricholic Acid 0.054 0.003 0.7 0.07 0.020 0.000 0.9 0.09 Glycodeoxycholic Acid 0.199 0.040 0.2 0.02 -0.095 0.009 0.5 0.06 Glycolithocholic Acid 0.079 0.006 0.6 0.06 -0.019 0.000 0.9 0.09 Glycoursodeoxycholic Acid 0.081 0.007 0.6 0.05 -0.041 0.002 0.8 0.08 Glyco-w-Muricholic Acid 0.233 0.054 0.1 0.02 -0.286 0.082 0.05 0.02 Glycoallocholic Acid 0.077 0.006 0.6 0.06 0.022 0.000 0.9 0.09 Taurocholic Acid -0.004 0.000 1.0 0.1 -0.029 0.001 0.8 0.09 Taurochenodeoxycholic Acid -0.035 0.001 0.8 0.08 -0.033 0.001 0.8 0.08 Taurohyocholic Acid 0.026 0.001 0.9 0.08 -0.081 0.007 0.6 0.06 Tauro-a-Muricholic Acid 0.056 0.003 0.7 0.07 -0.057 0.003 0.7 0.07 Tauro-|3-Muricholic Acid 0.307 0.094 0.03 0.008 -0.074 0.005 0.6 0.06 Taurodeoxycholic Acid 0.198 0.040 0.2 0.02 -0.206 0.042 0.2 0.03 Taurolithocholic Acid 0.403 0.162 0.005 0.003 -0.328 0.107 0.02 0.01 Tauroursodeoxycholic Acid -0.010 0.000 0.9 0.1 -0.035 0.001 0.8 0.08

[0276]

[0277] Tauro-w-Muricholic Acid 0.061 0.004 0.7 0.07 -0.055 0.003 0.7 0.07Table 11. Correlations between changes in sulfated and glucuronidated fecal bile acids and changes in constipation and changes in fecal bile acids and changes in diarrhea in participants consuming 3.5g RPS.

[0278] Constipation Correlation Diarrhea Correlation Bile Acid

[0279] Pearson R2P q Pearson R P q Value Value2

[0280] Value Value Cholic Acid-3-Sulfate -0.100 0.010 0.5 0.05 -0.048 0.002 0.7 0.07 Cholic Acid-7-Sulfate 0.458 0.209 0.001 0.002 -0.375 0.141 0.009 0.008 Chenodeoxycholic Acid-3-Sulfate 0.377 0.143 0.008 0.005 -0.367 0.135 0.01 0.008 Hyocholic Acid-3-Sulfate 0.250 0.062 0.09 0.01 -0.248 0.062 0.09 0.02 Deoxycholic Acid-3-Sulfate 0.485 0.235 0.0005 0.0008 -0.369 0.136 0.01 0.009 Lithocholic Acid-3-Sulfate 0.485 0.235 0.0005 0.0005 -0.360 0.130 0.01 0.009 Ursodeoxycholic Acid-3-Sulfate 0.303 0.094 0.04 0.008 -0.231 0.053 0.1 0.02 Ursodeoxycholic Acid-7-Sulfate 0.248 0.062 0.09 0.01 -0.310 0.096 0.03 0.02 Hyodeoxycholic Acid-3-Sulfate 0.466 0.217 0.0009 0.002 -0.441 0.195 0.002 0.002 Allocholic Acid-3-Sulfate 0.272 0.074 0.06 0.01 -0.288 0.083 0.05 0.02 Isolithocholic Acid-3-Sulfate 0.390 0.152 0.006 0.004 -0.310 0.096 0.03 0.02 Glycocholic Acid-3-Sulfate -0.064 0.004 0.7 0.06 -0.010 0.000 0.9 0.1 Glycochenodeoxycholic Acid-3- 0.028 0.001 0.9 0.08 -0.003 0.000 1.0 0.1 Sulfate

[0281] Glycodeoxycholic Acid-3-Sulfate 0.406 0.165 0.004 0.003 -0.224 0.050 0.1 0.02 Glycolithocholic Acid-3-Sulfate 0.198 0.039 0.2 0.02 -0.131 0.017 0.4 0.05 Glycoisolithocholic Acid-3-Sulfate 0.157 0.025 0.3 0.03 -0.088 0.008 0.5 0.6 Glycoursodeoxycholic Acid-3-Sulfate -0.030 0.001 0.8 0.08 -0.062 0.004 0.7 0.07 Glycoallocholic Acid-3-Sulfate -0.063 0.004 0.7 0.06 0.000 0.000 1.0 0.1 Taurochenodeoxycholic Acid-3- 0.201 0.040 0.2 0.02 -0.204 0.041 0.2 0.03 Sulfate

[0282] Taurodeoxycholic Acid-3-Sulfate -0.079 0.006 0.6 0.06 -0.008 0.000 1.0 0.1 Taurolithocholic Acid-3-Sulfate 0.018 0.000 0.9 0.09 -0.079 0.006 0.6 0.06 Tauroursodeoxycholic Acid-3-Sulfate -0.068 0.005 0.6 0.06 -0.056 0.003 0.7 0.07 Chenodeoxycholic Acid-3- -0.010 0.000 0.9 0.1 -0.343 0.118 0.02 0.01 Glucuronide

[0283] Lithocholic Acid-3-Glucuronide -0.035 0.001 0.8 0.08 -0.069 0.005 0.6 0.07

[0284]

[0285] Lithocholic Acid-24-Glucuronide 0.072 0.005 0.6 0.06 -0.130 0.017 0.4 0.05Table 12. Correlations between changes in sulfated serum bile acids and changes in constipation and changes in fecal bile acids and changes in diarrhea in participants consuming 3.5g RPS.

[0286] Constipation Correlation Diarrhea Correlation

[0287] Bile Acids

[0288] Pearson R2p Value Pearson R2p Value

[0289] Cholic Acid-3-Sulfate -0.165 0.027 0.3 0.166 0.028 0.3 Chenodeoxycholic Acid-3-Sulfate -0.275 0.076 0.06 0.016 0.000 0.9

[0290] Deoxycholic Acid-3-Sulfate -0.158 0.025 0.3 0.15 0.000 0.9

[0291] Lithocholic Acid-3-Sulfate -0.156 0.024 0.3 0.041 0.002 0.8 Ursodeoxycholic Acid-3-Sulfate -0.085 0.007 0.6 0.030 0.001 0.8 Hyodeoxycholic Acid-3-Sulfate 0.017 0.000 0.9 0.054 0.003 0.7

[0292] Glycocholic Acid-3-Sulfate 0.237 0.056 0.1 0.083 0.007 0.6 Glycochenodeoxycholic Acid-3-Sulfate 0.015 0.000 0.9 0.083 0.007 0.6 Glycodeoxycholic Acid-3-Sulfate 0.094 0.009 0.5 0.067 0.004 0.7 Glycolithocholic Acid-3-Sulfate -0.057 0.003 0.7 0.090 0.008 0.5 Glycoallocholic Acid-3-Sulfate 0.124 0.015 0.4 0.262 0.069 0.08 Glycohyodeoxycholic Acid 3-sulfate 0.003 0.000 1.0 0.035 0.001 0.8 Taurochenodeoxycholic Acid-3-Sulfate 0.039 0.002 0.8 0.255 0.065 0.08 Taurodeoxycholic Acid-3-Sulfate 0.024 0.001 0.9 0.142 0.020 0.3 Taurolithocholic Acid-3-Sulfate 0.048 0.002 0.7 0.176 0.031 0.2

[0293]

[0294] Tauroursodeoxycholic Acid-3-Sulfate 0.036 0.001 0.8 0.059 0.003 0.7References

[0295] [1] M. Field, "Intestinal ion transport and the pathophysiology of diarrhea," J Clin Invest, vol. 111, no. 7, pp. 931-943, 2003.

[0296] [2] S. Mehravar, W. Takakura, J. Wang, M. Pimentel, J. Nasser and A. Rezaie, "Symptom Profile of Patients With Intestinal Methanogen Overgrowth: A Systematic Review and Meta-analysis," Clin Gastroenterol Hepatol, In press.

[0297] [3] M. Pimentel, H. Lin, P. Enayati, B. van den Burg, H.-R. Lee, J. Chaen, S. Park, Y. Kong and J.

[0298] Conklin, "Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity," Am J Physiol Gastroenterol Liver Physiol, vol.

[0299] 290, pp. G1089-G10895, 2006.

[0300] [4] Y. Xu and Z. Xue, "The relationship between food components and constipation: a cross- sectional study," BMC Gastroenterology, vol. 24, no. 1 , p. 459, 2024.

[0301] [5] A. van der School, C. Drysdale, K. Whelan and E. Dimidi, "The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials," Am J Clin Nutr, vol. 116, no. 4, pp. 953-969, 2022.

[0302] [6] D. Bliss, H. Jung, K. Savik, A. Lowry, M. Le Moine, L. Jensen, C. Werner and K. Schaffer, "Supplementation with dietary fiber improves fecal incontinence," Nurs Res, vol. 50, no. 4, pp. 203-213, 2001.

[0303] [7] J. Jalanka, G. Major, K. Murray, G. Singh, A. Nowak, C. Kurtz, I. Silos-Santiago, J. Johnston, W.

[0304] de Vos and R. Spiller, "The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls," IntJ Mol Sci, vol. 20, no. 2, p. 433, 2019.

[0305] [8] J. J. McRorie, R. Gibb, K. Sloan and N. McKeown, "Psyllium: The Gel-Forming Nonfermented Isolated Fiber That Delivers Multiple Fiber-Related Health Benefits," Nutrition Today, vol. 56, no. 4, pp. 169-182, 2021.

[0306] [9] G. Gibson, R. Hutkins, M. Sanders, S. Prescott, R. Reimer, S. Salminen, K. Scott, C. Stanton, K. Swanson, P. Cani, K. Verbeke and G. Reid, "Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics," Nat Rev Gastro Hepatol, vol. 14, pp. 491-502, 2017.

[0307]

[0010] R. Hutkins, J. Walter, G. Gibson, C. Bedu-Ferrari, K. Scott, D. Tancredi, A. Wijeyesekera and S.

[0308] ME, "Classifying compounds as prebiotics - scientific perspectives and recommendations," Nat Rev Gastroenterol Hepatol, vol. 22, no. 1 , pp. 54-70, 2025.

[0011] C. Di Rosa, A. Altomare, V. Terrigno, F. Carbone, J. Tack, M. Cicala and M. Guarino, "Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms," Nutrients, vol. 15, no. 7, p. 1647, 2023.

[0309]

[0012] S. Eswaran, W. Chey, T. Han-Markey, S. Ball and K. Jackson, "A Randomized Controlled Trial Comparing the Low FODMAP Dietvs. Modified NICE Guidelines in US Adults with IBS-D," Am J Gastroenterol, vol. 111 , no. 12, pp. 1824-1832, 2016.

[0310]

[0013] J. Bush, J. Baisley, S. Harding and M. Alfa, "Consumption of Solnul™ Resistant Potato Starch Produces a Prebiotic Effect in a Randomized, Placebo-Controlled Clinical Trial," Nutrients, vol. 15, no. 7, p. 1582, 2023.

[0311]

[0014] J. Bush and M. Alfa, "Consumption of resistant potato starch produces changes in gut microbiota that correlate with improvements in abnormal bowel symptoms: a secondary analysis of a clinical trial," BMC Nutr, vol. 10, no. 1 , p. 152, 2024.

[0312]

[0015] M.Alfa, D. Strang, P. Tappia, N. Olson, P. DeGagne, D. Bray, B. Murray and B. Hiebert, "A Randomized Placebo Controlled Clinical Trial to Determine the Impact of Digestion Resistant Starch MSPrebiotic® on Glucose, Insulin, and Insulin Resistance in Elderly and Mid -Age Adults," Front Med (Lausanne), vol. 4, p. 260, 2018.

[0313]

[0016] M. Alfa, D. Strang, P. Tappia, M. Graham, G. Van Domselaar, J. Forbes, V. Laminman, N.

[0314] Olson, P. DeGagne, D. Bray, B. Murray, B. Dufault and L. Lix, "A randomized trial to determine the impact of a digestion resistant starch composition on the gut microbiome in older and mid-age adults," Clin Nutr, vol. 37, no. 3, pp. 797-807, 2018.

[0315]

[0017] E. Deehan, C. Yang, M. Perez-Munoz, N. Nguyen, C. Cheng, L. Triador, Z. Zhang, J. Bakal and J.

[0316] Walter, "Precision Microbiome Modulation with Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production," Cell Host Microbe, vol. 27, no. 3, pp. 389-404, 2020.

[0317]

[0018] S. Lewis and K. Heaton, "Stool form scale as a useful guide to intestinal transit time," ScandJ Gastroenterol, vol. 32, no. 9, pp. 920-924, 1997.

[0318]

[0019] J. Bush, J. Han, E. Deehan, S. Harding, M. Maiya, J. Baisley, D. Schibli and D. Goodlett, "Resistant potato starch supplementation reduces serum histamine levels in healthy adults with links to attenuated intestinal permeability," J Funct Foods, vol. 108, p. 105740, 2023.

[0319]

[0020] J. Han, K. Lin, C. Sequria, J. Yang and C. Borchers, "Quantitation of low molecular weight sugars by chemical derivatization-liquid chromatography / multiple reaction monitoring / mass spectrometry," Electrophoresis, vol. 37, no. 13, pp. 1851-1860, 2016.

[0320]

[0021] J. Han, S. Gagnon, T. Eckle and C. Borchers, "Metabolomic analysis of key central carbon metabolism carboxylic acids as their 3-nitrophenylhydrazones by UPLC / ESI-MS," Electrophoresis, vol. 34, no. 19, pp. 2891-2900, 2013.

[0022] J. Han, Y. Liu, R. Wang, J. Yang, V. Ling and C. Borchers, "Metabolic Profiling of Bile Acids in Human and Mouse Blood by LC-MS / MS in Combination with Phospholipid-Depletion Solid- Phase Extraction," Anal Chem, vol. 87, no. 2, pp. 1127-1136, 2014.

[0321]

[0023] Y. Benjamini and H. Y, "Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing," JR StatSoc Ser B Methodol, vol. 57, no. 1, pp. 289-300, 1995.

[0322]

[0024] L. Zhai, C. Huang, Z. Ning, Y. Zhang, M. Zhuang, W. Yang, X. Wang, J. Wang, L. Zhang, H. Xiao, L. Zhao, P. Asthana, Y. Lam, C. Chow, J.-D. Huang, S. Yuan, K. Chan, C.-S. Yuan, J.-N. Lau, H. Wong and Z.-X. Bian, "Ruminococcus gnavus plays a pathogenic role in diarrhea- predominant irritable bowel syndrome by increasing serotonin biosynthesis," Cell Host Microbe, vol. 31 , no. 1 , pp. 33-44, 2023.

[0323]

[0025] J. Yano, K. Yu, G. Donaldson, G. Shastri, P. Ann, L. Ma, C. Nagler, R. Ismagilov, S. Mazmanian and E. Hsaio, "Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis," Cell, vol. 161, no. 2, pp. 264-276, 2015.

[0324]

[0026] W. Wagner, K. Sobierajska, L. Putaski, A. Stasiak and W. Ciszewski, "Whole grain metabolite 3,5-dihydroxybenzoic," Crit Rev Food Sci Nutr, vol. 64, no. 24, pp. 8786-8804, 2023.

[0325]

[0027] V. Schmieden and H. Betz, "Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds," Mol Pharmacol, vol. 48, no. 5, pp. 919-927, 1995.

[0326]

[0028] D. Thwaites, L. Basterfield, P. McCleave, S. Carterand N. Simmons, "Gamma-Aminobutyric acid (GABA) transport across human intestinal epithelial (Caco-2) cell monolayers," Br J Pharmacol, vol. 129, no. 3, pp. 457-464, 2000.

[0327]

[0029] K. Yamasaki and Y. Goto, "Acid secretagogue action of structurally gamma-aminobutyric acid (GABA)-related compounds in rats," Jpn J Pharmacol, vol. 52, no. 2, pp. 255-262, 1990.

[0328]

[0030] W. Zygmunt, R. Evans and H. Stavely, "Diastereoisomers of p-hydroxyaspartic acid as aspartic acid antagonists in bacteria," Arch Biochem Biophys, vol. 102, no. 2, pp. 270-275, 1963.

[0329]

[0031] S. Shames, D. Ash and F. V. J. Wedler, "Interaction of aspartate and aspartate-derived anti metabolites with the enzymes of the threonine biosynthetic pathway of Escherichia coli," J Biol Chem, vol. 259, no. 24, pp. 15331-15339, 1984.

[0330]

[0032] T. Ishiyama, T. Furuta, M. Takai and Y. Okimoto, "L-threo-beta-hydroxyaspartic acid as an antibiotic amino acid," J Antibiot (Tokyo), vol. 28, no. 10, pp. 821-823, 1975.

[0331]

[0033] M. Liu, J. Rothstein, M. Gershon and A. Kirchgessner, "Glutamatergic enteric neurons," J Neurosci, vol. 17, no. 12, pp. 4764-4784, 1997.

[0034] A. Farrugia and R. Arasaradnam, "Bile acid diarrhoea: pathophysiology, diagnosis and management," Frontline Gastroenterol, vol. 12, no. 6, pp. 500-507, 2020.

[0332]

[0035] H. Mekjian, S. Phillips and A. Hofmann, "Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man," J Clin Invest, vol. 50, no. 8, pp. 1569-1577, 1971.

[0333]

[0036] A. Di Ciaula, G. Garruti, R. Baccetto, E. Molina-Molina, L. Bonfrate, D.-H. Wang and P.

[0334] Portincasa, "Bile acid physiology," Ann Hepatol, vol. 16, no. Suppl 1 , pp. S4-S14, 2017.

[0335]

[0037] N. Breuer, D. Rampton, A. Tammar, G. Murphy and R. Dowling, "Effect of colonic perfusion with sulfated and nonsulfated bile acids on mucosal structure and function in the rat," Gastroenterology, vol. 84, no. 5 Pt 1 , pp. 969-977, 1983.

[0336]

[0038] A. Hofmann, V. Loening-Baucke, J. Lavine, L. Hagey, J. Steinbach, C. Packard, T. Griffin and D.

[0337] Chatfield, "Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients," J Pediatric Gastroenterol Nutr, vol.

[0338] 47, no. 5, pp. 598-606, 2008.

[0339]

[0039] L. Feng, Y.-L. Yuen, J. Xu, X. Liu, M.-C. Chan, K. Wang, W.-P. Fong, W.-T. Cheung and S.-T. Lee, "Identification and characterization of a novel PPARa-regulated and 7a-hydroxyl bile acidpreferring cytosolic sulfotransferase mL-STL (Sult2a8)," J Lipid Res, vol. 58, no. 6, pp. 1114- 1131, 2017.

[0340]

[0040] M. Dew, P. Hawker, S. Nutter and R. Allan, "Human intestinal sulphation of lithocholate: A new site for bile acid metabolism," Life Sciences, vol. 27, no. 4, pp. 317-323, 1980.

[0341]

[0041] J. Robben, P. Caenepeel, J. Van Eldere and H. Eyssen, "Effects of intestinal microbial bile salt sulfatase activity on bile salt kinetics in gnotobiotic rats," Gastroenterology, vol. 94, no. 2, pp.

[0342] 494-502, 1988.

[0343]

[0042] P. Dawson and K. Setchell, "Will the real bile acid sulfotransferase please stand up? Identification of Sult2a8 as a major hepatic bile acid sulfonating enzyme in mice," J Lipid Res, vol. 58, no. 6, pp. 1033-1035, 2017.

[0344]

[0043] X. Zhou, Y. He, J. Chen, X. Xiong, J. Yin, J. Liang, C. Peng, C. Huang, G. Guan and Y. Yin, "Colonic phosphocholine is correlated with Candida tropicalis and promotes diarrhea and pathogen clearance," NPJ Biofilms Microbiomes, vol. 9, no. 1 , p. 62, 2023.

[0345]

[0044] P. Zhang, Y. Chen, T. Zhang, J. Zhu, L. Zhao, J. Li, G. Wang, Y. Li, S. Xu, A. Nilsson and R.-D.

[0346] Duan, "Deficiency of alkaline SMase enhances dextran sulfate sodium-induced colitis in mice with upregulation of autotaxin," J Lipid Res, vol. 59, no. 10, pp. 1841-1850, 2018.

[0347]

[0045] M. Omar, R. Barrio, G. Pereira-Caro, T. Almutairi and A. Crozier, "In vitro catabolism of 3', 4'- dihydroxycinnamic acid by human colonic microbiota," IntJ Food Sci Nutr, vol. 72, no. 4, pp.

[0348] 511-517, 2021.

[0046] G. Williamson and M. Clifford, "A critical examination of human data for the biological activity of phenolic acids and their phase-2 conjugates derived from dietary (poly)phenols, phenylalanine, tyrosine and catecholamines," Crit Rev Food Sci Nutr, vol. 65, no. 27, pp. 5324-5383, 2025.

[0349]

[0047] M. Peppercorn and P. Goldman, "Caffeic acid metabolism by bacteria of the human gastrointestinal tract," J Bacterial, vol. 108, no. 3, pp. 996-1000, 1971.

[0350]

[0048] A. Breynaert, D. Bosscher, A. Kahnt, M. Claeys, P. Cos, L. Pieters and N. Hermans, "Development and Validation of an in vitro Experimental Gastrointestinal Dialysis Model with Colon Phase to Study the Availability and Colonic Metabolisation of Polyphenolic Compounds," Planta Med, vol. 81 , no. 12-13, pp. 1075-1083, 2015.

[0351]

[0049] T. Itoh, A. Tomiyasu and K. Tamamoto, "Efficient synthesis of the very-long-chain n-3 fatty acids, tetracosahexaenoic acid (C24:6n-3) and tricosahexaenoic acid (C23:6n-3)," Lipids, vol. 46, no. 5, pp. 455-461 , 2011.

[0352]

[0050] F. Barba, N. Nikmaram, S. Roohinejad, A. Khelfa, Z. Zhu and M. Koubaa, "Bioavailability of Glucosinolates and Their Breakdown Products: Impact of Processing," Front Nutr, vol. 3, p.

[0353] 24, 2016.

[0354]

[0051] Y. Wu, R. Li, H. Huang, A. Fletcher, L. Yu, Q. Pham, L. Yu, Q. He and T. Wang, "Inhibition of Tumor Growth by Dietary lndole-3-Carbinol in a Prostate Cancer Xenograft Model May Be Associated with Disrupted Gut Microbial Interactions," Nutrients, vol. 11 , no. s, p. 467, 2019.

[0355]

[0052] K. Brawner, V. Yeramilli, L. Duck, W. Van Der Pol, L. Smythies, C. Morrow, C. Elson and C.

[0356] Martin, "Depletion of dietary aryl hydrocarbon receptor ligands alters microbiota composition and function," Sci Rep, vol. 9, no. 1 , p. 14724, 2019.

[0357]

[0053] Z. Lin, Y. Feng, J. Wang, Z. Men and X. Ma, "Microbiota governs host chenodeoxycholic acid glucuronidation to ameliorate bile acid disorder induced diarrhea," Microbiome, vol. 13, no.

[0358] 1, p. 36, 2025.

[0359]

[0054] W. Zhu, Q. Cheng, C. Liu, J. Qian, J. Xu and X. Wang, "LTr1 alleviates DSS-induced ulcerative colitis by modulating macrophages to inhibit M1 polarization and associated inflammatory responses," Front Immunol, vol. 16, p. 1651922, 2025.

[0360]

[0055] S.-q. Wang, L.-s. Cheng, Y. Liu, J.-y. Wang and W. Jiang, "lndole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection," CurrDrug Metab, vol. 17, no. 4, pp. 401-409, 2016.

[0361]

[0056] Y. Liu, Z. Pei, T. Pan, H. Wang, W. Chen and W. Lu, "Indole metabolites and colorectal cancer:

[0362] Gut microbial tryptophan metabolism, host gut microbiome biomarkers, and potential intervention mechanisms," Microbiol Res, vol. 272, p. 127392, 2023.

[0363]

[0057] T. Zelante, R. lannitti, C. Cunha, A. De Luca, G. Giovannini, G. Pieraccini, R. Zecchi, C.

[0364] D’Angelo, C. Massi-Benedetti, F. Fallarino, A. Carvalho, P. Puccetti and L. Romani,"Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22," Immunity, vol. 39, no. 2, pp. 372-385, 2013.

[0365]

[0058] R. Ejima, R. Mishima, A. Sen, K. Yamaguchi, E. Mitsuyama, H. Kaneko, M. Kimura, S. Arai, N.

[0366] Muto, A. Hiraku, K. Kato, Y. Kuwano, H. Maruyama, M. Nakamura, N. Iwabuchi, M. Nakano, T. Odamaki and M. Tanaka, "The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial," Nutrients, vol. 16, no. 21 , p. 3580, 2024.

[0367]

[0059] K. Murray, R. Adams, J. Earl and K. Shaw, "Studies of the free faecal amines of infants with gastroenteritis and of healthy infants," Gut, vol. 27, no. 10, pp. 1173-1180, 1986.

[0368]

[0060] M. Santoru, C. Piras, A. Murgia, V. Palmas, T. Camboni, S. Liggi, I. Ibba, M. La, S. Orru, S.

[0369] Blois, A. Loizedda, J. Griffin, P. Usai, P. Caboni, L. Atzori and A. Manzin, "Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients," Sci Rep, vol. 7, p. 9523, 2017.

[0370]

[0061] Y. Tanaka, R. Yamashita, J. Kawashima, H. Mori, K. Kurokawa, S. Fukuda, Y. Gotoh, K.

[0371] Nakamura, T. Hayashi, Y. Kasahara, Y. Sato and S. Fukudo, "Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation," J Gastroenterol, vol. 57, no. 10, pp. 748-760, 2022.

[0372]

[0062] G. Wu, N. Zhao, C. Zhang, Y. Lam and L. Zhao, "Guild-based analysis for understanding gut microbiome in human health and diseases," Genome Med, vol. 13, no. 22, pp.

[0373] 10.1186 / sl 3073-021 -00840-y, 2021.

[0374]

[0063] A. Rangarajan, H. Chia, C. Azaldegui, M. Olszewski, G. Pereira, N. Koropatkin and J. Biteen, "Ruminococcus bromii enables the growth of proximal Bacteroides thetaiotaomicron by releasing glucose during starch degradation," Microbiology (Reading), vol. 168, no. 4, p. 10.1099 / mic.0.001180, 2022.

[0375]

[0064] W. Wagner, K. Sobierajska, L. Putaski, A. Stasiak and W. Ciszewski, "Whole grain metabolite 3,5-dihydroxybenzoic acid is a beneficial nutritional molecule with the feature of a doubleedged sword in human health: a critical review and dietary considerations," Grit Rec Food Sci Nutr, vol. 64, no. 24, pp. 8786-8804, 2024.

[0376]

[0065] M. Lind, M. Madsen, J. Rumessen, H. Vestergaard, R. Gobel, T. Hansen, L. Lauritzen, O.

[0377] Pedersen, M. Kristensen and A. Ross, "Plasma Alkylresorcinols Reflect Gluten Intake and Distinguish between Gluten-Rich and Gluten-Poor Diets in a Population at Risk of Metabolic Syndrome," J Nutr, vol. 140, no. 10, pp. 1991-1998, 2016.

[0378]

[0066] G. Rocchetti, L. Lucini, G. Giuberti, S. Bhumireddy, R. Mandal, M. Trevisan and D. Wishart, "Transformation of polyphenols found in pigmented gluten-free flours during in vitro large intestinal fermentation," Food Chem, vol. 298, p. 125068, 2019.

[0067] F. Manza, L. Lungaro, A. Costanzini, F. Caputo, A. Carroccio, P. Mansueto, A. Seidita, S. Raju, U. Volta, R. De Giorgio, D. Sanders and G. Caio, "Non-Celiac GlutenA / Vheat Sensitivity-State of the Art: A Five-Year Narrative Review," Nutrients, vol. 17, no. 2, p. 220, 2025.

[0379]

[0068] J. Goedert, J. Sampson, S. Moore, Q. Xiao, X. Xiong, R. Hayes, J. Ahn, J. Shi and R. Sinha, "Fecal metabolomics: assay performance and association with colorectal cancer," Carcinogenesis, vol. 35, no. 9, pp. 2089-2096, 2014.

[0380]

[0069] D. Brown, S. Rao, T. Weir, J. O'Malia, M. Bazan, R. Brown and E. Ryan, "Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool," Cancer Metab, vol. 4, p. 11 , 2016.

[0381]

[0070] S. Wright and T. Secomb, "Epidermal taurine transport in marine mussels," Am J Physiol, vol.

[0382] 247, no. 2 Pt 2, pp. R346-355, 1984.

[0383]

[0071] H. Wang, A. Ainiwaer, Y. Song, L. Qin, A. Peng, H. Bao and H. Qin, "Perturbed gut microbiome and fecal and serum metabolomes are associated with chronic kidney disease severity," Microbiome, vol. 11 , no. 1 , p. 3, 2023.

[0384]

[0072] R. Greenberg, J. Dunn and R. Guerrant, "Reduction of the secretory response to Escherichia coli heat-stable enterotoxin by thiol and disulfide compounds," Infect Immun, vol. 41, no. 1, pp. 174-180, 1983.

[0385]

[0073] S. Karlsson, A. Lindberg, E. Norin, L. Burman and T. Akerlund, "Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile," Infect Immun, vol. 68, no. 10, pp. 5881-5888, 2000.

[0386]

[0074] M. van Ampting, A. Schonewille, C. Vink, R. Brummer, R. van der Meer and I. Bovee- Oudenhoven, "Intestinal barrier function in response to abundant or depleted mucosal glutathione in Salmonella-infected rats," BMC Physiol, vol. 9, p. 6, 2009.

[0387]

[0075] T. Tsuchiya, H. Honda, M. Oikawa, T. Kakita, A. Oyama, H. Oishi, K. Tochikubo, T. Hashimoto, S. Kurihara, T. Shibakusa and T. Kayahara, "Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients," IntJ Clin Oncol, vol. 21 , no. 6, pp. 1085-1090, 2016.

[0388]

[0076] R. Hamaguchi, T. Tsuchiya, G. Miyata, T. Sato, K. Takahashi, K. Miura, H. Oshio, H. Ghori, K.

[0389] Ariyoshi and S. I. S. Oyamada, "Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JGRTC-CAM03)," Support Care Cancer, vol. 28, no. 8, pp. 3649-3657, 2020.

[0390]

[0077] J. Yoneda, S. Nishikawa and S. Kurihara, "Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model," BMC Cancer, vol. 21 , no. 1 , p. 1343, 2021.

[0078] G. Bruno, A. Gagliardi, A. Oliva, M. Trancassini, A. Macone, C. Cicerone, A. DAbramo, V. lebba, S. Auria, G. Bonfiglio, M. Zingaropoli, G. D'Ettorre, D. Badiali, V. Vullo, E. Corazziari and S. Schippa, "Fecal MicrobialTransplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent Clostridium difficile infection patients," New Microbiol, vol. 42, no. 4, pp. 221-224, 2019.

[0391]

[0079] J. Meadows and M. Wargo, "Carnitine in bacterial physiology and metabolism," Microbiology (Reading), vol. 161 , no. Pt 6, pp. 1161 -1174, 2015.

[0392]

[0080] S. Turroni, J. Fiori, S. Rampelli, S. Schnorr, C. Consolandi, M. Barone, E. Biagi, F. Fanelli, M.

[0393] Mezzullo, A. Crittenden, A. Henry, P. Brigidi and M. Candela, "Fecal metabolome of the Hadza hunter-gatherers: a host-microbiome integrative view," Sci Rep, vol. 6, p. 32826, 2016.

[0394]

[0081] J. Lloyd-Price, C. Arze, A. Ananthakrishnan, M. Schirmer, J. Avila-Pacheco, T. Poon, E.

[0395] Andrews, N. Ajami, K. Bonham, C. Brislawn, D. Casero, H. Courtney, A. Gonzalez, T. Graeber, A. Hall, L. K, C. Landers, H. Mallick, D. Plichta and e. al, "Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases," Nature, vol. 569, no. 7758, pp. 655-662, 2019.

[0396]

[0082] J. Lemons, M. Conrad, C. Tanes, J. Chen, E. Friedman, M. Roggiani, D. Curry, L. Chau, A.

[0397] Hecht, L. Harling, J. Vales, K. Kachelries, R. Baldassano, M. Goulian, K. Bittinger, S. Master, L. Liu and G. Wu, "Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease," Cell Mol Gastroenterol Hepatol, vol.

[0398] 17, no. 1, pp. 131-148, 2024.

[0399]

[0083] W. YY, W. Gou, Y. Yan, C. Liu, Y. Yang, D. Chen, K. Xie, Z. Jiang, Y. Fu, H. Zhu, J. Zheng and Y.

[0400] Chen, "Gut microbiota and acylcarnitine metabolites connect the beneficial association between equol and adiposity in adults: a prospective cohort study," Am J Clin Nutr, vol. 116, no. 6, pp. 1831-1841, 2022.

[0401]

[0084] K. Schwenger, D. Sharma, Y. Ghorbani, W. Xu, W. Lou, E. Comelli, S. Fischer, T. Jackson, A.

[0402] Okrainec and J. Allard, "Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients," Liver Int, vol. 44, no. 5, pp. 1176-1188, 2024.

[0403]

[0085] D. Boedeker and H. Martens, "Urinary orotic acid excretion in sheep: effects of nitrogen, glucose and arginine," J Nutr, vol. 120, no. 9, pp. 1001-1005, 1990.

[0404]

[0086] K. Trost, L. Ahonen, T. Suvitaival, N. Christiansen, T. Nielsen, M. Thiele, S. Jacobsen, A. Krag, P. Rossing, T. Hansen, L. Dragsted and C. Legido-Quigley, "Describing the fecal metabolome in cryogenically collected samples from healthy participants," Sci Rep, vol. 10, no. 1 , p. 885, 2020.

[0405]

[0087] M. Laursen, M. Sakanaka, N. von Burg, U. Mbrbe, D. Andersen, J. Moll, C. Pekmez, A. Rivollier, K. Michaelsen, C. Molgaard, M. Lind, L. Dragsted, T. Katayama, H. Frandsen, A. Vinggaard, M. Bahl, S. Brix, W. Agace, T. Licht and H. Roager, "Bifidobacterium species associated withbreastfeeding produce aromatic lactic acids in the infant gut," Nat Microbiol, vol. 6, no. 11 , pp. 1367-1382, 2021.

[0406]

[0088] F. Fernandez-Banares, "Carbohydrate Maldigestion and Intolerance," Nutrients, vol. 14, no. 9, p. 1923, 2022.

[0407]

[0089] S. Lindell and R. Schayer, "Metabolism of injected [14C] histamine in the kidney of the dog," Br J Pharmacol Chemother, vol. 13, no. 1 , pp. 52-53, 1958.

[0408]

[0090] Y. Zeng, Q. ,. W. G. Man, T. Fangyuan, J. Chunxia, C. Jiao, T. Xiaozhen, Z. Chen, Y. Long, B.-K.

[0409] Law and X. Yong, "Gut microbiota-derived imidazole propionate: an emerging target for the prevention and treatment of cardiometabolic diseases," Front Endocrinol, vol. 16, p.

[0410] 1409119, 2025.

[0411]

[0091] A. Koh, A. Molinaro, M. Stahlman, M. Khan, C. Schmidt, L. Manneras-Holm, H. Wu, A.

[0412] Carreras, H. Jeong, L. Olofsson, P.-O. Bergh, V. Gerdes, A. Hartstra, M. de Brauw, R. Perkins, M. Nieuwdorp, G. Bergstrom and F. Backhed, "Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORCI," Cell, vol. 175, no. 4, pp. 947-961, 2018.

[0413]

[0092] J. Bush, I. Iwuamadi, J. Han, D. Schibli, D. Goodlett and E. Deehan, "Resistant Potato Starch Supplementation Reduces Serum Free Fatty Acid Levels and Influences Bile Acid Metabolism," Metabolites, vol. 14, no. 10, p. 536, 2024.

[0414]

[0093] R. Venskutonyte, A. Koh, O. Stenstrbm, M. Khan, A. Lundqvist, M. Akke, F. Backhed and K.

[0415] Lindkvist-Petersson, "Structural characterization of the microbial enzyme urocanate reductase mediating imidazole propionate production," Nat Comm, vol. 12, p. 1347, 2021.

[0416]

[0094] S. Bathena, S. Mukherjee, M. Olivera and Y. Alnouti, "The profile of bile acids and their sulfate metabolites in human urine and serum," J Chromatogr B Analyt Technol Biomed Life Sci, Vols. 942-943, pp. 53-62, 2013.

[0417]

[0095] J. Reardon, T. Hussaini, M. Alsahafi, V. Azalgara, S. Erb, N. Partovi and E. Yoshida, "Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review," J Clin Transl Hepatol, vol. 4, no. 3, pp. 192-205, 2016.

[0418]

[0096] S. Jang, T. Lee, S. Jeong, C. Kwon, D. Koh, Y. Kim, H. Lee, M. Do, J. Cho and D. Lee, "Efficacy of Chenodeoxycholic Acid and Ursodeoxycholic Acid Treatments for Refractory Functional Dyspepsia," J Clin Med, vol. 11 , no. 11 , p. 3190, 2022.

[0419]

[0097] E. Jacobs, M. Haussler, D. Alberts, L. Kohler, P. Lance, M. Martinez, D. Roe and P. Jurutka, "Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations," Cancer Prev Res (Phila), vol. 9, no. 7, pp. 589-597, 2016.

[0420]

[0098] E. Loftfield, E. Vogtmann, J. Sampson, S. Moore, H. Nelson, R. Knight, N. Chia and R. Sinha, "Comparison of collection methods for fecal samples for discovery metabolomics inepidemiological studies," Cancer Epidemiol Biomarkers Prev, vol. 25, no. 11 , pp. 1483-1490, 2017.

[0421]

[0099] X. Chen, T.-T. Qiu, Y. Wang, L.-Y. Xu, J. Sun, Z.-H. Jiang, W. Zhao, T. Tao, Y.-W. Zhou, L.-S. Wei, Y.-Q. Li, Y.-Y. Zheng, G.-H. Zhou, H.-Q. Chen, J. Zhang, X.-B. Feng, F.-Y. Wang, N. Li, X.-N. Zhang, J. Jiang and M.-S. Zhu, "A Shigella species variant is causally linked to intractable functional constipation," J Clin Invest, vol. 132, no. 14, p. e150097, 2022.

[0422]

[0100] L. Humbert, M. Maubert, C. Wolf, H. Duboc, M. Mahe, D. Farabos, P. Seksik, J. Mallet, G.

[0423] Trugnan, J. Masliah and D. Rainteau, "Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients," J Chromatogr B Analyt Technol Biomed Life Sci, vol. 899, pp. 135-145, 2012.

[0424]

[0101] J. Fleishman and S. Kumar, "Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets," Sign Transduct Target Ther, vol. 9, p. 97, 2024.

Claims

CLAIMS1. A method of modifying levels of a microbially-influenced metabolite in the large intestine of an individual generated by resistant potato starch fermentation in the individual’s gut comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

2. The method according to claim 1 wherein the microbially-influenced metabolite is a biogenic amine, amino acid, dibasic amino acid, polyamine, carnitine, purine metabolite, dibasic sugar, vitamin, neurotransmitter, or alkyresorcinol fermentation product.

3. The method according to claim 1 wherein the microbially-influenced metabolite is selected from the group consisting of phenylethylamine, 3,5-dihydroxybenzoic acid, cystine, N1-acetyl putrescine, beta-aminobutyric acid, thiamine, 3-hydroxyhexadecanoylcarnitine, 3-methylcrotonyl-L-carnitine, orotic acid, propionylcarnitine, maltose, lactose, 2-methylbutyrylcarnitine, phenyllactic acid, serotonin, or cysteine.

4. A method of decreasing fecal phenylethylamine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

5. The method accordingto claim 4 wherein the individual in need of such treatment has baseline fecal phenylethylamine levels higher than 2.8 nM / g.

6. The method according to claim 4 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

7. The method accordingto claim 4 wherein the individual in need of such treatment has a disorder for which diarrhea is a primary symptom or complaint, irritable bowel syndrome, inflammatory bowel disease, or some other intestinal condition.

8. The method according to claim 4 wherein the individual in need of such treatment is supplementingtheir diet with phenylethylamine or foods rich in phenylalanine there is provided use of native RPS (RS type 2) for diarrhea reduction.

9. A method of decreasing fecal 3,5-dihydrobenzoic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

10. The method according to claim 9 wherein the individual in need of such treatment has fecal 3,5-dihydrobenzoic acid levels higher than 0.67 pmol / g dry fecal material.

11. The method according to claim 9 wherein the individual in need of such treatment suffers from frequent diarrhea, for example, irritable bowel syndrome associated diarrhea or inflammatory bowel disease, including Crohn’s disease,12. The method according to claim 9 wherein the individual in need of such treatment suffers from non-celiac gluten sensitivity or is sensitive to fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs).

13. The method according to claim 9 wherein the individual in need of such treatment is consuming foods containing wheat, barley, rye, quinoa, orfoods rich in alkylresorcinols.

14. A method of decreasing fecal beta-aminobutyric acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

15. The method according to claim 14 wherein the individual in need of such treatment has fecal beta-aminobutyric acid levels that are higher than a control individual.

16. The method according to claim 14 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

17. A method of decreasing fecal thiamine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

18. The method accordingto claim 17 wherein the individual in need of such treatment has fecal thiamine levels that are higher than a control individual.

19. The method accordingto claim 17 wherein the individual in need of such treatment is supplementing theirdiet with thiamine orfoods rich in thiamine.

20. A method of preventing the increase in fecal serotonin levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

21. The method accordingto claim 20 wherein the individual in need of such treatment has fecal serotonin levels higher than 5 + / -18 nmol / g.

22. The method accordingto claim 20 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

23. The method accordingto claim 20 wherein the individual in need of such treatment is supplementing their diet with serotonin or consuming foods rich in tryptophan.

24. A method of increasing fecal cystine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

25. The method according to claim 24 wherein the individual in need of such treatment has fecal cystine levels are lower than a control individual.

26. The method according to claim 24 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

27. A method of increasing fecal N1 -acetyl putrescine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

28. The method accordingto claim 27 wherein the individual in need of such treatment has fecal N1 -acetyl putrescine levels lower than 100 ng / 0.05 mL of fecal supernatant.

29. The method accordingto claim 27 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

30. A method of increasing fecal 3-hydroxyhexadecanoylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

31. The method accordingto claim 30 wherein the individual in need of such treatment has total fecal acylcarnitine levels lower than 14.0 nmol / g feces.

32. The method according to claim 30 wherein the individual in need of such treatment has fecal levels of hydroxyhexadecanoylcarnitine lower than 0.2 nmol / g.

33. The method accordingto claim 30 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

34. A method of increasing fecal 3-methylcrotonyl-L-carnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

35. The method according to claim 34 wherein the individual in need of such treatment has total fecal acylcarnitine levels lowerthan 14.0 nmol / gfeces.

36. The method according to claim 34 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome- related diarrhea or incontinence.

37. A method of increasing fecal orotic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

38. The method accordingto claim 37 wherein the individual in need of such treatment has fecal orotic acid levels that are lower than a control individual.

39. The method accordingto claim 37 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

40. A method of increasing fecal propionylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

41. The method accordingto claim 40 wherein the individual in need of such treatment has total acylcarnitine levels lowerthan 14.0 nmol / gfeces.

42. The method accordingto claim 40 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

43. A method of increasing fecal maltose levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

44. The method accordingto claim 43 wherein the individual in need of such treatment has fecal maltose levels that are lower than a control individual.

45. The method accordingto claim 43 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

46. A method of increasing fecal lactose levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

47. The method accordingto claim 46 wherein the individual in need of such treatment has fecal lactose levels that are lowerthan a control individual.

48. The method accordingto claim 46 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

49. The method accordingto claim 46 wherein the individual in need of such treatment is lactose intolerant or has a milk allergy.

50. A method of increasing fecal 2-methylbutyrylcarnitine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

51. The method accordingto claim 50 wherein the individual in need of such treatment has total fecal acylcarnitine levels lower than 14.0 nmol / g.

52. The method accordingto claim 50 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

53. A method of increasing fecal phenyllactic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

54. The method accordingto claim 53 wherein the individual in need of such treatment has fecal phenyllactic acid levels lower than 20.4 nmol / g feces.

55. The method accordingto claim 53 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

56. A method of increasing fecal lactic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

57. The method accordingto claim 56 wherein the individual in need of such treatment has fecal lactic acid levels lower than 5 pmol / g feces.

58. The method accordingto claim 56 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

59. A method of increasing fecal cysteine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

60. The method accordingto claim 59 wherein the individual in need of such treatment has fecal cysteine levels lower than a control individual.

61. The method accordingto claim 59 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

62. A method of increasingfecaltaurine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

63. The method accordingto claim 62 wherein the individual in need of such treatment has fecal taurine levels lower than a control individual.

64. The method accordin to claim 62 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

65. The method accordingto claim 1 wherein the resistant potato starch is administered daily for a period of 1-12 weeks. In this context, “daily” does not necessarily mean “every day” but may mean for example 19 out of 20 days, 9 out of 10 days, 17 out of 20 days or 8 out of 10 days.

66. The method accordingto claim 1 wherein the effective amount may be, for example, 0.5 to 40g, or 0.5 to 30g, or 0.5 to 7g, or 0.5 to 3.5g of resistant starch.

67. The method accordingto claim 1 wherein the microbially-influenced metabolite is a fatty acid, imidazole acid, bile acid, sulfated bile acid, hydroxyamino acid, or phosphorylated choline.

68. The method accordingto claim 1 wherein the microbially-influenced metabolite is selected from the group consisting of 1-methyl-4-imidazoleacetic acid, imidazolepropionic acid, linoleyl carnitine , hyodeoxycholic acid-3-sulfate, 3-hydroxyaspartic acid, palmitoylcarnitine, myristoylcarnitine, oleoylcarnitine, ursodeoxycholic acid, chenodeoxycholic acid, phosphocholine, isobutyrylcarnitine, FA(16:0-OH), lithocholic acid-3-sulfate, deoxycholic acid-3-sulfate, cholic acid-7-sulfate, or FA(22:5).

69. A method of increasingfecal 1-methyl-4-imidazoleacetic acid levels in an individual in need of such treatment comprisingadministeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

70. The method according to claim 69 wherein the individual in need of such treatment has urine 1-methyl-4-imidazoleacetic acid levels lower than 1.25 umol / mmol creatinine.

71. The method according to claim 69 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome- related diarrhea or incontinence.

72. A method of increasingfecal imidazolepropionic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

73. The method accordingto claim 72 wherein the individual in need of such treatment has urine imidazolepropionic acid levels lower than 1.25 umol / mmol creatinine.

74. The method according to claim 72 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

75. A method of increasing fecal linoleyl carnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

76. The method accordingto claim 75 wherein the individual in need of such treatment has total fecal acylcarnitine levels lower than 14.0 nmol / g.

77. The method accordingto claim 75 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

78. A method of increasing fecal hyodeoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

79. The method accordingto claim 78 wherein the individual in need of such treatment has fecal hyodeoxycholic acid-3-sulfate levels lower than those in a control individual.

80. The method accordingto claim 78 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

81. A method of increasing fecal 3-hydroxyaspartic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

82. The method according to claim 81 wherein the individual in need of such treatment has fecal 3-hydroxyaspartic acid levels lowerthan those in a control individual.

83. The method according to claim 82 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome- related diarrhea or incontinence.

84. A method of increasing fecal palmitoylcarnitine levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

85. The method according to claim 84 wherein the individual in need of such treatment has total fecal acylcarnitine levels lowerthan 14.0 nmol / g.

86. The method accordingto claim 84 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

87. A method of increasing fecal myristoylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

88. The method accordingto claim 87 wherein the individual in need of such treatment has total fecal acylcarnitine levels lower than 14.0 nmol / g.

89. The method accordingto claim 87 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

90. A method of increasing fecal oleoylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

91. The method accordingto claim 90 wherein the individual in need of such treatment has total fecal acylcarnitine levels lower than 14.0 nmol / g.

92. The method accordingto claim 90 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

93. A method of increasing fecal ursodeoxycholic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

94. The method according to claim 93 wherein the individual in need of such treatment has fecal ursodeoxycholic acid levels 27.05 nmol / g dry feces.

95. The method according to claim 93 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome- related diarrhea or incontinence.

93. A method of increasing fecal chenodeoxycholic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

94. The method according to claim 93 wherein the individual in need of such treatment has fecal chenodeoxycholic acid levels lower than 54.8 nmol / g dry feces.

95. The method according to claim 93 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

96. A method of increasing fecal isobutyrylcarnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

97. The method according to claim 96 wherein the individual in need of such treatment has total fecal acylcarnitine levels lower than 14.0 nmol / g.

98. The method according to claim 96 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

99. A method of decreasing fecal FA(16:0-OH) levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

100. The method according to claim 99 wherein the individual in need of such treatment has fecal FA(16:0-OH) levels higher than a control individual.

101. The method according to claim 99 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

102. A method of decreasing fecal lithocholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

103. The method according to claim 102 wherein the individual in need of such treatment has fecal lithocholic acid-3-sulfate levels higher than 0.77 nmol / g dry feces.

104. The method according to claim 102 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

105. A method of decreasing fecal deoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

106. The method according to claim 105 wherein the individual in need of such treatment has fecal deoxycholic acid-3-sulfate levels higher than 9.36 nmol / g dry feces.

107. The method according to claim 105 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

108. A method of decreasing fecal imidazolepropionic acid levels in an individual in need of such treatment comprising administeringto said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

109. The method according to claim 108 wherein the individual in need of such treatment has urine imidazolepropionic acid levels higherthan 1.25 umol / mmol creatinine.

110. The method according to claim 108 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

111. A method of decreasing fecal 1-methyl-4-imidazoleacetic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

112. The method according to claim 111 wherein the individual in need of such treatment has urine 1-methyl-4-imidazoleacetic acid levels higherthan 1.25 umol / mmol creatinine.

113. The method accordingto claim 111 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

114. A method of decreasing fecal hyodeoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

115. The method accordingto claim 114 wherein the individual in need of such treatment has fecal hyodeoxycholic acid-3-sulfate levels higherthan 9.36 nmol / g dry feces.

116. The method accordingto claim 114 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

117. A method of decreasing fecal cholic acid-7-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

118. The method accordingto claim 117 wherein the individual in need of such treatment has fecal cholic acid-7-sulfate levels higherthan those in a control individual.

119. The method accordingto claim 117 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

120. A method of decreasing fecal FA(22:5) levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

121. The method according to claim 120 wherein the individual in need of such treatment has urine FA(22:5) levels are higher than 6.4 pmol / mmol creatinine.

122. The method according to claim 120 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

123. The method according to claim 120 wherein the individual in need of such treatment has elevated levels of FA(22:5)-producing Shigella bacteria in the gut.

124. A method of decreasing fecal linoleyl carnitine levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

125. The method according to claim 124 wherein the individual in need of such treatment has fecal linoleyl carnitine levels are higher than 0.36 nmol / gwet feces.

126. The method according to claim 124 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

127. The method according to claim 1 wherein the microbially-influenced metabolite is selected from the group consisting of glycodeoxycholic acid-3-sulfate, caffeic acid, FA(24:6), indole-3-carbinol, or indole-3-aldehyde.

128. A method of decreasing fecal glycodeoxycholic acid-3-sulfate levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

129. The method according to claim 128 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

130. A method of decreasing fecal caffeic acid levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

131. The method according to claim 130 wherein the individual in need of such treatment has baseline caffeic acid levels in fecal water above 52 ± 47 pmol / L.

132. The method according to claim 130 wherein the individual in need of such treatment has frequent constipation, irritable bowel syndrome-related constipation or intractable functional constipation.

133. A method of decreasing fecal FA(24:6) levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

134. The method according to claim 133 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

135. A method of decreasing fecal indole-3-carbinol levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

136. The method according to claim 135 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.

137. A method of decreasing fecal indole-3-aldehyde levels in an individual in need of such treatment comprising administering to said individual an effective amount of a suitable resistant potato starch on a dosage regimen.

138. The method according to claim 137 wherein the individual in need of such treatment has frequent diarrhea, irritable bowel syndrome-related diarrhea or incontinence.